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INTRODUCTION 
 In the ancient period Indian Saints handle the plants and herbs for long life 
with better health and lived more than thousand years of age. They were called as 
“Siddhars” and their system of medicine was known as Siddha system. 
 Siddha system is one of the unique system of Indian medicine. According to 
Siddha Physiology man is considered as the „microcosm‟ universe is considered as 
the “macrocosm” It shows the human body is the replica of the universe. 
   ‘mz;lj;jp Ys;sNj gpz;lk; 
   gpz;lj;jp Ys;sNj mz;lk; 
   mz;lKk; gpz;lKk; xd;Nw 
   mwpe;J jhd; ghh;f;Fk; NghNj” 
       -rl;lKdp Qhdk; 
 
 Siddha system is differ from the other system of medicine by giving obsolute 
physical mental and social well being of an individual by its various tools like 
medicine, Meditation, yoga, varmam, massage and its distinctive social and 
preventive medicine which is quoted by Theraiyar in pini anugavithy. 
 Thirumoolar quotes that.. 
   kWg;gJ cly;Neha; kUe;jdyhFk; 
   kWg;gJ csNeha; kUe;njdr;rhYk; 
   kWg;gJ ,dp Neha; thuhjpUf;f 
   kWg;gJ rhitAk; kUehjdhyhNk” 
 It can be Sammarized that the siddha system is primarily universal and is 
principally focused on preventive health. 
 On the basis of our Siddha text Ostoarthritis is inter correlated with Keelvaayu 
and more often keel vaayu comes under 80 types of Vadha diseases in Yugi Vaithiya 
Chinthamani -800 one among them is „AZHAL KEEL VAYU” 
 Osteoarthritis is a chronic degenerative disorder of multi factorial etiology 
characterized by loss of articular cartilage, hypertrophy of bone at the margins. 
Subchondral sclerosis and range of bio chemical and morphological alterations of 
the synovial membrane and Joint capsule. 
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 Osteoarthritis most often involves the joints that bear most of your body 
weight (weight bearing joints) such as the knee or hip. Osteoarthritis can also occurs 
in any other joints, such as lower spine or the joints in the hands an finger. 
 Primary osteoarthritis is mostly related to aging. It can present as localized, 
generalized or as erosive osteoarthritis. Secondary osteoarthritis is usually followed 
by another disease. It is the second most common rheumatological problem and it is 
the most frequent joint disease with prevalence of 25% to 45% in India. 
Osteoarthritis the most common form of arthritis is a major contributor to functional 
impairment and reduced independence in older adult. 
 In adults 45 years and over the most common site of peripheral joint pain 
lasting for the moren than one week in the past month is in the knee (19%) and the 
highest prevalence of knee pain is amoungst women aged 75 and over (35%). Global 
disability is also high amongst those reporting isolated knee pain. In adult aged 50 
years and over 23% report severe pain and disability. 
 A variety of causes hereditary, developmental, metabolic and mechanical 
deficits may initiate processes leading to loss of cartileges when bone surfaces 
become less protected by cartilage, bone may be exposed and damaged. 
 As a result of decreased movement secondary to pain, regional muscles and 
ligaments may atropohy when the severeity increases invasive treatment may be 
needed. 
The author have selected the KALINGA MATHERAI  (Internal) to 
evaluate their therapeutic efficacy in the treatment of Azhal Keel Vayu 
(OSTEOARTHRITIS) as above said drug formulation has not undergone any 
clinical so far. 
Internal Medicine  
       KALINGA MATHERAI-Gunapadam mooligai(Page No. 91).The dosage   of 
the trail medicine is 65mg(BD) for 48 days. 
External Medicine 
 KODIVELI THYLAM -Gunapadam mooligai(Page no.385) with the dosage -60ml 
(for external application)  
External therapy  
            PATTRU –Gunapadam mooligai (pg.no 61) 
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The above medicine contains ingredients which have anti vadha property. 
Considering this they are chosen as trial medicines in this study. pattru is one of the 
best external therapies in Siddha system of medicine.  
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AIM AND OBJECTIVE 
 
AIM: 
 Phase 11 clinical observation criteria based study of Azhal Keel Vayu 
(OSTEOARTHRITIS) and the drug choice, KALINGA MATHIRAI (internal) and KODIVELI 
THYLAM (external) and external therapy PATTRU 
OBJECTIVE: 
 
Primary Objective: 
 To evaluate the clinical efficiency of „KALINGA MATHIRAI” (internal) and 
“KODIVELI THYLAM” (external) in the treatment of “AZHAL KEEL VAYU” 
(OSTEOARTHRITIS) and external therapy PATTRU  for the reduction of pain and swelling and 
to improve the range of movement. 
 
SECONDARY OBJECTIVE: 
 To evaluate reduction in restriction of movements. 
 To evaluate effect of pattru along with trial medicines 
 To study the Siddha principles before and after treatment. 
 To evaluate the safety profile of the trial medicine. 
 To evaluate the pharmacological study of trial medicine. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT: 
 Siddhars spiritual scientist explored and explain the reality of nature and its 
relationship to man by their yogic awareness. 
 According to Siddha philosphy man is nothing but a miniature world 
containing the five basic elements. 
 The Earth give shape to the body and release its energy, Bones, Muscles 
nerves represent it in the body. 
 Panchaboothas namely earth, water, fire, air and either which correspondents 
to the five sense of the human body and they. 
 The water makes the earth supply and helps in the transmission of energy, 
Serum, Lymph Saliva etc, represent it in the body. 
 The fire makes the form of the body steady and gives vigour and stimulation, 
Digestion and circulation represent it in the body. 
 The air ignites the fire and works as a life carrier and is the support of all 
contact and exchange. Respiratory and nervous system represent it in the body. The 
either is the creater of life itself in the body. 
 A harmonious combination and function of these five elements in the body 
produce a healthy life. Man has gross physical body and subtle physical body. The 
life force which is different from material energy derived from food, pervades the 
gross physical through the subtle physical. 
Thiruvalluvar says 
   “kpfpDk; FiwapDk; Neha; nra;Ak; E}Nyhh; 
   tspKjyh vz;zpa %d;W” 
 The food we eat has six tastes namely Sweet (,dpgG). Sour (Gspg;G), Salt 
(cg;G), Bitler (ifg;G), Purngent (fhh;g;G), Astringent (Jth;g;G) 
 Each of it is a Mixture of two basic elements 
    ifg;G  - kz; + ePh; 
    Gspg;G  - kz; + jP 
    cg;G  - ePh; + jP 
    ifg;G  - fhw;W + Mfhak; 
    Jth;g;G - kz; + Mfhak; 
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Three humours theory: 
 Pachaboothas are the foundations for Thridosha (Vatham, Pitham Kabham) 
which are described in Siddha Medicine is a golden line continuous in phyciology, 
pathology and treatment. The three humours vatham, pitham and kapham whose 
balance is essential for maintenance of good health. 
  “thjkha; gilj;J gpj;j td;dpaha; fhj;J Nrj;k 
  fPjkha; Jilj;J” 
       - Njiuah; kUj;Jt ghujk; 
  Vaayu constitute vatham 
  Theyu constitute pitham 
  Appu constitute Kabham 
 Any alterations in the level of Thridhosha affects the normal functions of the 
body. This is obvious from the verses. 
   “kpfpDk; FiwapDk; Neha;nra;Ak; E}Nyhh; 
   tspKjyh ntz;zpa %d;W” 
      -jpUf;Fws; (kUe;J) 
The normal order of Vatha, Pitha, Kaba, is in proportion of 1: ½ : ¼ respectively. 
    
                toq;fpa thjk; khj;jpiu nahd;whhpy; 
   joq;fpa gpj;jk; jz;zpiuthfp 
   moq;Fq; fge;jhdlq;fpNa fhNyhby; 
   guq;fpa rPth;f;F gprnfhd;Wkpy;iyNa 
 Any changes in these proportions will be responsible for disease but the 
maintenance of their normal proportion gives vitality to the organism and assures the 
preservation of health and longevity of life. 
Thannilai Valarchi (Accumulation and excitation) 
 The stage where the humour accumulates in a particular part as stagnant is 
called Thannilai Valarchi. 
 When the stagnant humour accumulated and permeated a structure there is an 
excitement from eversion towards similar and attraction towards contraries. This is 
known as „prakobam‟ 
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Piranilai Valarchi (Spreading) 
 This is the stage where the excited humour extends by viyana to another part. 
The derangement of kutram becomes located in part of the body. And being to cause 
disease of Joints, blood, stomach, bladder and soon. 
I. Vatham 
Own qualities of Vatham (6) 
  Dry (tul;rp) 
  Cold(Fsph;r;rp) 
  Subtle(mZj;Jtk;) 
  Rough(fbdk;) 
  Unstable(mirjy;) 
  Light(,yF) 
opposite qualities of vatham (6) 
  Unctuous - (gRik) 
  Hot (mf;fpdp) 
  Solid (nfl;b) 
  Soft (kpUJ) 
  Stable (];jpuk;) 
  Heavy (gST) 
Location of Vatham: 
 Vatham is located in the hip, below the abdomen, Moolatharam and sexual 
organs it is also said that vatha is settled in various places including bone, joints, 
nerves, vessels, hairfollicles, muscles, sperm, urine and stools. 
Function of Vatham: 
 The function of vatham is stimulates the body and soul, voiding of excreta 
refreshness and proper harmony of the seven thathu. 
Effect of vitiated vatha: 
 Vayu-pain, exquisite pain, extreme dryness, palpitation, dislocation of the 
joints dysfunction of the sexual organs, constipation, dysuria, thirst, pain in the long 
bone unable to flexion and extension of the limal, dark complexion and emaciation 
are the main ill effects of the vitiated vatha. 
11. Pitham: 
 The term pitham denotes gastric juice, bile, energy, heat and anger at    
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own qualities of pitham (6) 
  Hot (mf;fpdp) 
  Acid(Gspg;G) 
  Mobile (CLe;jd;ik) 
  Liquid(ry&gk;) 
  Acute (F&uk;) 
  Pungent (fhuk;) 
   
Opposite qualities of pitham (6) 
  Cold(Fsph;r;rp) 
  Sweet(,dpg;G) 
  Immobile(epiyj;jpUj;jy;) 
  Solid(nfl;b) 
  Mild or harmless(rhe;jk;) 
  Bitter(frg;G) 
Location of Pitha: 
 Head, Heart, Bladder, Abdomen, Umbilicus, Stomach, Saliva, Sweat, Blood, 
Eyes and skin are the sites of pitham. 
Effects of vitiated pitham: 
 Excessive heat in the body, improper digestion, excessive sweat, gridiness 
syncope and immortal behaviours are some of the ill effects of vitiated pitham. 
III. Kabam: 
Own qualities of Kabam (6) 
  Cold (Fsph;r;rp) 
  Heavy(gST) 
             Immobile (mirtpd;ik) 
  Sweet (,dpg;G) 
  Soft (kpUJ) 
  Unctuous (<uk;) 
  viscid (totog;G) 
Opposite qualities of kabam (6) 
  Hot (cl;bzk;) 
  Light (,yF) 
  Mobile(mirjy;) 
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  Pungent (fhuk;) 
  Rough (fbdk;) 
  Dry(twl;rp) 
  Sandy (fufug;G) 
Location of Kabam 
 The Kabam is located in the tongue, chest, blood, bone marrow, bones, 
nerves, brain, large intestine, eyes and joint. 
Functions of Kabam: 
 The important functions of kabam are maintaining the viscosity and proper 
functioning of the joints. 
Effects of vitiated kabam: 
 Pain in the long bones, dysfunction of the joints, improper digestion, 
excessive sleep and inhibition of understanding capacity. 
Relation between suvai, panchapootham and Thiridhosam. 
S.No. Suvai Panchapootham Thiridhosam 
1 Inippu Man + Neer Kabam  
Vatham  (-) 
Pitham  (+) 
2 Pulippu Man + Thee Kabam  
Pitham 
Vatham  (-) 
3 Uppu Neer + Thee Kabam  
Pitham  
Vatham (-) 
4 Kaippu Vayu + Aagayam Vatham  
Kabam  (-) 
Pitham  (-) 
5 Kaarppu Vayu + Thee Vatham  
Pitham  (-) 
Vatham  (-) 
6 Thuvarppu Man + Vayu Vatham  
Kabam  
Pitham  (-) 
 
  - Vetrunilai Valarchi 
  - Thannilai Valarchi 
  (-) - Thannilai Adaithal 
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KEEL VAYU 
 In Siddha literature Azhal Keel Vayu comes under the topic of Vatha disease. 
Keel Vayu is the general term that include all kind of Joint diseases. (Locomotor 
system) 
    Azhal Keel Vayu = Azhal + Keel + Vayu 
    Azhal - Pitham 
    Keel - Joint 
    Vayu - Vatham 
 In „Yugi Vaithiya Sinthamani Vatha diseases are classified into 80 types. 
 In Theryar Vagadam Vatham into 81 types Keel Vayu comes under the 
classification of 81 types of Vatham. 
 TV Sambasivam pillai Dictionary “Keel Vayu” means painful inflamation 
with Swelling affecting the muscle and Joints of the human body. 
 In Agasthiyar Gunavagasdam „Keel Vayu” comes under the 80 types of Vatha 
diseases. 
   „jhdhf fPy;thj Nuhfk; Ngiu 
   Neha; jdf;F ghfpaha; thjNuhf nkd;ghh; 
   El;gKs;s thjNuhf nkz;gJe; jhd; 
   Ma;e;njLj;J ,jw;Fs;Ns Mf;fk; ghU” 
      -mfj;jpah; Fzthflk; 
Other Names: 
 According to Siddha Maruthuvam textbook Keel Vaayu mentioned as Santhu 
Vali, Muttu Vali, Magha Soolai, Mudakku Vayu, Ama Vatham. 
 Vitiated vatham, produces disease in Keel (Joints) called as Keel Vayu” 
 Pain in muthu (joint) called - Muttuvali 
 Disease which followed by Megha noi called as - “Megha Soolai” 
 Inability to use Joints properly called as -“Mudakku Vayu” 
 Pain present in all joints called as -“Santhuvali” 
 In proper digestion of food followed by increased Kapham produces Vadha disease 
called as -Amavatham” 
 In Yakobu Vidhya sinthamani it is mentioned a „Mudakku Vatha Soolai” In 
Thanvanthri Vaidya Kaviyam it is said as „Mudakku Vaya” Iyal (Definition) 
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    „thpAike; jd;dpiy nfl;L 
   typAld; tPf;fr; ruKk; fha;e;J 
   %l;Lfs; NjhWk; KLf;fpNa nehe;J 
   %l;Lfs; jd;dpy; ePUk; Rue;J 
   jhq;nfhzh typAkh nehe;jpLk;Nk” 
      -rghgjp ifNaL 
 Keel Vayu is a Vatha disease characterized by pain and swelling of the joints, 
stiffness of the muscles and joints with tenderness frequently associated with fever, 
anorexia and insomnia. It may be accompanied by emaciation, anaemia and 
restriction of joint movements and in some cases even immobility may occur. 
 According to agasthiar guna vagadam “Keel Vayu” comes under the 80 types 
Vatha disease. 
   „typA ikAe; jd;dpiy nfl;L 
   typAld; tPf;fr; RuKk; fha;e;J 
   Kl;Lf NlhWk; KLf;fpNa nehe;J 
   Kl;Lf ld;dpd; ePUk; Rue;J 
   jhq;nfhzh typAld; nehe;jpL kk;Nk” 
       -rghgjp ifNaL 
    
   „jhdhf fPy;thj Nuhfk; Ngiu 
   Neha; jdf;F ghfpaha; thjNuhf nkz;ghh; 
   El;gKs;s thjNuhf nkd;gJe; jhd; 
   Ma;e;njLj;J ,jw;Fs;Ns mlf;fk; ghU” 
      -mfj;jpah; Fzthflk; 
Noi Enn (Classification) 
 Keel Vayu is classified into 10 types according to Siddha Maruthuvam text 
book. 
 Vali Keel Vayu 
 Azhal Keel Vayu 
 Iya Keel Vayu 
 Vali azhal Keel vayu 
 Vali iyal keel vayu 
 Azhal Vali Keel vayu 
 Azhal iyal Keel vayu 
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 Iya Voli Keel Vayu 
 Iya ahzla keel vayu 
 Mukkutra Keel vayu 
In theraiyar vagadam among the 81 vatha disease following are joint diseases. 
 Sooriya vatham 
 Seetha vatham 
 Jozhi vatham 
 Kuthi vatham 
 Santhu vatham 
 Vasi vatham 
 Kendai vatham 
 Sathi vatham 
 Thombai vatham 
 Kotai vatham 
  In the text book Athma rakshamirtham, the following are described as 
Joint disease. 
 Muzhanthai vatham 
 Mudakku vatham 
 Kendaikal vatham 
 Santhu vatham 
 Thoal vatham 
 Muzhi vatham 
Noi Varum Vazhi (Aetiology) 
  “fhzNt kpfTz;lhYq; fUYgl;bdp tpl;lhYk; 
  khd;idahh; fz; Nkfkwf;fpD kpFe;jpahYk; 
  Mzt kyq;flk;ik aq;qNd tplhjjhYk; 
  thDjd; kley; yhNd thjq;Nfh gpf;Fq;fhNd” 
       -guuhr Nrfuk; 
  mjpf msT cz;zy;> gl;bdp fplj;jy;> 
  Mztk; mjpfhpj;jy; Mfpatw;whYk; 
  „ghhpdpw; gag;gl;lhYk; gyFld; Nfhgpj;jhYk; 
  fhnudf; fUjpNahbf; fKkuj; Juj;jpdhYk; 
  Vh;ngW jdJ neQ;rpy; kpfj; Jf;fkile;jpl;lhYk; 
  ghhpa fhw;wpdhYk; glhpDk; thjq;fhZk; 
       -guuhr Nrfuk; 
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gak;> vy;NyhhplKk; Nfhgk; nfhs;sy;> kpFjpahf Jf;fk; jpdKk; clypd;Nky; 
fhw;Wgly; Nghd;wtw;whYk; 
  „fhyq;fz; khwpAz;Zq; fhhpaj; jhYe; jz;zPh; 
  rhyNt aUe;jpdhYe; re;jpYl; fhe;jhYk; 
  Nfhykhk; Gspg;G nea;ia tUe;jpdhYk; 
  thy;thh; Kiy ey;yhNs thj Kw;gzpf;Fq;fhNz” 
      -guuhr Nrfuk; 
  „$WnkdhW %d;Wld; FyT ehiye; NjopYk; 
  Fw;wkhk; eyj;jpDk; nfhuk; gd;dpuz;bYk; 
  NruNt Gjd;jhWNkh rphpaNkid epd;hpby; 
  nrg;nghzhj jPikNahL nra;Ak; gr;re;jhWk; 
  neLe;Jf;f kpf;fthk; elf;fw;jhJ njhopy;jhk 
  epjijahF fPygpbg;G ePL nka;apy; Njhd;Wkhk; 
  fhhpaq;fs; Nrjkha; fhy;taJ FiwAkhk; 
  fz;Lzh;e;J afzpj ty;Nyhd; fUj;Jld; nrg;gpdNk” 
      -kzpke;jpu itj;jpa Nrfuk;” 
 
  vd;dNt thjk; jhndd;gjhFk; 
  ,fj;jpNy kdpjh;fSf;F nra;Athw 
  gpd;dNt nghd;jidNa Nfhuq;nra;J 
  nghpNahh;fs; gpuhkziuj; J}$bdpj;Jk; 
  td;Njth; nrhj;jpr; NrhuQ; nra;J 
  khjh gpjh FUit kwe;j Ngh;f;Fk; 
  fd;dNt Ntfj;ij epe;ij nra;jy; 
  fhaj;jpy; fye;jpLNk thje;jhNd” 
    -A+fp rpe;jhkzp ghly; 243 
  „tspAike; jd;dpiy nfl;L 
  typAld; tPf;fr; RuKk; fha;e;J 
  %l;Lfs; NjhWk; KLf;fpNa nehe;J 
  %l;Lfs; jd;dpy; ePUk; Rue;J 
  jhq;nfhzh typAkh nehe;jpLNk” 
 Vatha disease is caused due to the following precipitating factors: 
 Increased intake of tubers 
 wandering of chill weather 
 Drenching in rain 
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 Living in hilly region 
 Excessive sexual inter course 
  Heredity 
 Excessive intake of bitter, astringent, acrid taste food, intake of varagu, thinai and 
altered sleep pattern also contribute to vatha disease. 
External Cause: 
Environmental factors: 
thjth;j; jd fhyNkNfh ntd;fpy; 
kUTfpd;w Mdp fw;fl khjk; 
Mjidg; grpNahL fhj;jpif jd;dpy; 
ml;UNk kw;w khjq;fs; jd;dpy; 
NghfNt rkpf;fpd;w fhykhFk; 
   -A+fp rpe;jhkzp 
 The vatha disease will be precipitated in the months from Aani to Karthigai 
(June to December) 
 
 
„gJkj;ijg; G+f;f itf;Fk; ghDkpff; fhAk; 
KJNtdp ypw;G tpe;ePh; - fJnkd 
tw;Wk; fgk;‡Fk; thAkpFk; tho; khe;jh;f; 
Fw;w egpf; Nfjpnjd; NwhJ” 
    -rpj;j kUj;Jthq;f RUf;fk; 
 In Muthuvenil Kaalam, the increased Solar radiation increase the evaporation 
of water content in the world, on the same time this similar action on the body 
produces increases absorption of muucous for digestion and develop the vitality of 
vatha disease. So this disease occurs predominantly in muthuvenil kaalam. 
Diet: 
“tspjU fha; fpoq;F 
tiutpyh jkpy;y Nfhio 
Kspjaph; Nghd;kpFf;F 
Kiwapyh Tz;b Nfhly; 
Fsph;jU tspapw; Nwfq; 
Fspg;Gw Tyty; ngz;bh;fspj;jU Kaf;fk; ngw;Nwhh; 
fbnray; fUtpahky;”  
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 Diet and health which gives rise to vatha dhosa (i.e.) excessive intake of 
Potato like roots and banana, excessive intake of cold substances like curd, exposure 
to cold, staying in hill station which increase kabam causes this disease. 
 Further this disease is followed by Megha noi and may be hereditary physical 
factors. 
„gfuNt thjkJ Nghpj;jg;Ngh 
gz;ghf ngz;Nghfk; mDjhd; nra;apy; 
jfhNt ntFJ}u top elj;jpy; 
edpuhd fhw;WNk gzpNky; gl;lhy; 
epfuNt fha;fs; fdpfpoq;F jd;id 
kpU tUe;jp kPwpNa japh;jhd; nfhz;lhy; 
KfuNt KJnfYk;ig KWf;fp nehe;J 
Koq;fhYk; fZf;fhYk; fLg;Gz;lhFk; 
   -A+fp rpe;jhkzp 
 Indulging in the sexual act during vitlation of Vatha, walking for a long 
distance, exposing to dampress and cold, harmful combination like taking excessive 
curd after eating fruits, vegetables and tubers causes toxic factors which affects bone 
and muscles. 
 According to Pararasa Sekaram. 
njhopy; ngWifg;Gf; fhh;j;jy; Jth;j;jy; tpQ;RDQ;NrhWk; 
gioaJk; tuF kw;iwg; ige;jpidaUe;jpdhYk; 
vopy; ngwg; gfYwq;fp ,utpdpYwq;fhjyhYk; 
kio epfh; KoypdhNy thjq;Nf gpf;Fq;fhNd 
 Excessive intake of bitter, astringenet, pungent taste diet, day sleeping, 
wakening during night intake of old looked food items. 
Internal causes: 
Kanma as a cause: 
 In Siddha system, many diseases are said to be precipitated by Kanma, which 
means the deeds, good or bad committed by an individual in his previous and present 
births, Vatha diseases, according to agasthiyar Kanma kandam - 300 may also 
precipitated by Kanma. 
E}yd;w thjk; te;j tdfjhNdJ 
Jz;ikaha;f; fd;kj;j;jpd; tdfiaf; NfS 
fhypNy Njhd;wpaJ fLg;gNjJ 
iffhypy; Klf;fpaJ tPf;fNkJ 
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NfhypNy gLfpd;w tpUl;rkhd 
Foe;ij kue;jid ntl;ly; Nky; Njhy; rPty; 
E}ypNy rPt Ie;J fhy; Kwpj;jy; 
ey;y nfhk;G jioKwpj;jy; etpj;jy; jhNd 
    -mfj;jpahh; fd;k fz;lk;. 
 It attribute the following psychological factors such as removing the bark of 
living trees, cutting the trees in the living branches and removing leaves. 
 Due to karmic laws 
me;jzh; fw;G khjh; mUspa rhaj;jhYk; 
Ke;jpa tpidahYk; Kfph;fh;g;g Nkfj;jhYk; 
rpe;ijapw; nfhLikahYk; rptFU epe;ijahYe; 
njhe;jkhk; tpthjpahYk; Njhd;wpLk; FiyjhNd 
      -mfj;jpah; 
„E}nyd;w thjk; te;J tdfjhNdJ 
jd;ikaha;j; jd;kj;jpd; tifiaf; NfS 
fhypNy Njhd;wpaJ fLg;gNjJ 
iffhypy; Klf;fpaJ tPf;fNkJ 
NfhypNy gLfpd;w tUl;rkhd 
ey;ynfhk;G jioKwpj;jy; eypj;jy; jhNd 
     -mfj;jpah; fd;kfhz;lk; 
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Neha; tUk; top 
 
  taJ 
czT 
gof;ftof;fq;fs; 
thjk; 
tpahdd; 
mghdd; 
rkhdd; 
moy;fPo;thA 
gpj;jk; fgk; 
rhjfk; re;jpfk; 
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Clinical features 
„gpj;jf;fPy; tha;T jd;dhw; 
gpwq;FrPd; Kl;L tPq;fpr; 
rpj;jh;nra; kUe;J te;JQ; 
rph;glhj; jd;ikj; jhfpj; 
jj;JW fha;r;ry; fz;L 
 
rhyNt jidjhd; je;Nj 
nkj;jW rpfpr;ir jd;dhy; 
nkd;Nky; ePq;F kg;gh” 
    -rghgjp ifNaL  
 Swelling of the Joint 
 Fever 
 Restricted movement 
 Swelling of the Joint will increased day by day increased pitham act as synocid theid 
between the joint space which dries it. It makes sound like „kaluk, kaluk‟ when the 
movement of the joint. 
 Sometimes it may gpzpawp Kiwik (Diagnosis in Siddha): 
 gpzpawp Kiwik vd;gJ cliyg; gpzpj;jyhy; Nehiaj; njhpe;J 
nfhs;Sfpd;w xOf;fk; vdg;gLk;. 
tpjpAk; xOf;fKk; ,J 
 nghwpahw;Nwh;jy; 
 Gydhywpjy; 
 tpdhjy; 
nghwpahy; mwpjy; (Inspection): 
 “Poriyal Arithal” means examining the “Pori” of the patient by the physician 
for proper diagnosis. Pori is considered as the “Five sense organs” namely, 
1) nka; (Skin) 
2) ehf;F (Tongue) 
3) fz; (Eye) 
4) %f;F (Nose) 
5) nrtp (Ear) 
QhNde;jphpaq;fspd; Ma;T: 
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nrtp xypia mwpa nra;jy; ,ay;G 
nka; clypy; Cw;iw mwpjy; Koq;fhy; %l;Lfspy; tPf;fk;> typ 
fz; xspia mwpa nra;jy; ,ay;G 
ehf;F Ritia mwpa nra;jy; ,ay;G 
%f;F thrid Efu nra;jy; ,ay;G 
 
fd;Nke;jphpaq;fspd; Ma;T:- 
tha; trdpf;f nra;Ak; ,ay;G 
If ,LjYk;> Vw;wYk; nra;Ak; ,ay;G 
fhy; elf;fr; nra;Ak; Koq;fhy; %l;Lfspy; typ> elf;f rpukk; 
vUtha; kyj;ij fopf;Fk; kyr;rpf;fy; 
fUtha; fU> Rf;fpyj;ijf; fopf;Fk; ,ay;G 
 
 
Pulanal arithal (Palpation): 
Pulan are five senses. They are, 
1) ehw;wk; 
2) Rit 
3) xsp 
4) CW 
5) xir 
“Pulanal arithal” means examining the “Pulan” of the patient by the 
Physician to diagnose a disease. 
tpdhjy; (Interrogation): 
 tpdh vd;gJ Nfl;lwpjy;> nghwpahw;Nwh;jy;> Gydhywpjy;> tpdhjy; 
vd;gJ gpzpAw;Nwhdplj;Jk;> gpzp jPh;g;Nghdplj;Jk; cs;snghwp> Gyd;fs; 
gpzpfisj; njspthAzh;j;Jkhifahy; kUj;Jtd; jd;id Nehf;fp te;j 
gpzpAw;wtidg; gw;wp mwpa gpzpahsDila nghwp> Gyd; topaha; 
czh;tijf; Nfl;Lk; mtd; xUf;fhy; vf;fhuzj;jpdhNyh jhd; Nfl;gijr; 
nrhy;Ytjw;fpayhjtdhapUg;gpd; mtd; Rw;wj;jhiuf; nfhz;L 
mwpaf;$batiu mwpe;Jk;> gpzpiaf; fzpj;jiyg; gw;wpNa Fwpf;Fk;. 
 Vinaathal is gathering information regarding the history of disease, its clinical 
features etc., from the patient or his/her close relatives usually when the patient is 
not in a position to speak or in the case of a child. 
 20 
 
vz; tif Njh;T: 
 “Neha; ehb Neha; Kjy;ehb mJjzpf;Fk;  
 tha;ehb tha;g;gr; nray;”  - jpUf;Fws; 
1. ehb: 
 “thjj;jpy; Nrj;Jk khfpy; typNahL tPf;f Kz;lhk;” 
       mfj;jpah; ehb 
 “mwpe;Jghh; thjNk jdpj;jhdhy; 
 rhpe;jplNt fhy;Klf;Fk;” 
    mfj;jpah; uj;jpd RUf;fk; 
 “fhzg;gh thj kPwpy; fhy;iffs; nghUe;jp NehFk;” 
 thjk;> thjgpj;jk;> gpj;j thjk; - fhtpaehb 
2.];ghprk;:  
ghjpf;fg;gl;Ls;s %l;L gFjpapy; kpj ntg;gkhfNth> ,ay;ghfNth 
fhzg;gLk;. 
3. eh: 
 ,ay;G> thjNehapy; eh jbj;J ,Uf;Fk;. 
4. epwk;:  
 ,ay;G> khepwk; 
5. nkhop: 
 rkxyp 
6. tpop: 
 ,ay;G> thj Nehapy; tpop fWj;J ,ik jbj;jpUf;Fk; 
7. kyk;: 
 ghjpg;G (kyr;rpf;fy; fhzg;gLk;) 
8. %j;jpuk;: 
 %j;jpuk; fLg;Gld; nfhQ;rkhf EiuAld; ,wq;Fk; 
Neikkuri: 
 “mUe;J khwpjuKk; mtpNuhjkjha; 
 m/fy; myh;jy; mfhyt+d; jttph;e;jow; 
 Fw;ws tUe;jp cwq;fp itfiw 
 Mbf; fyrj; jhtpNa fhJnga; 
 njhU K$h;j;jf; fiyf;Fl; gLePhpd; 
 epwf;Fwp nea;f;Fwp epUkpj;jy; flNd” 
     - rpj;j kUj;Jthq;f RUf;fk;. 
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vd;gjdhy; cz;Zfpd;w mWRitg; nghUs;fSk; xd;Wf;nfhd;W 
Ntw;WikailahkYk; grpf;Fj; jf;fg;gb Fiwj;jy; mjpfhpj;jy;> fhye;jg;Gjy; 
Kjypa Fw;wq;fSz;lhfhtz;zk; Grpj;J cwq;fp tpbaw;fhyj;jpy; gbf 
ghj;jpuj;jpy; ePiu MtpNghfhjgb nga;j ehopiff;Fs; mjd; epwf; FwpiaAk;> 
mjpy; vz;nza;tpl;Lg; ghh;j;J fhzg;gLfpd;w FwpiaAk; ftdpj;J> gpzpfspd; 
jPUk; jPuhj Fwpfis nka;g;gpj;jy; Kiwahk;. 
vz;nza; tpl;Lg; ghh;f;Fk; ePhpd; tpjp: 
 epwf;Fwpf; Fiuj;j epUkhz ePhpw; 
 rpwf;f ntz;nza;Nahh; rpWJsp eLtpLj;  
 njd;Wwj; jpwe;njhyp Vfhjikj;jp  
 dpd;wjptiy Nghk; newptpopawpTk; 
 nrd;wJ GfYQ; nra;jpia AzNu 
     Neha;ehly; Neha; Kjy; ehly; gphpT-1 
 The collected specimen was examined by the subsequent method. The 
collected urine specimen is held in reserve in a glass dish or china clay container and 
experiential under direct sunlight without shaking the vessel. Then drip one drop of 
gingelly oil and observe the spreading pattern and concludes as follows, 
“muntd ePz;bd/Nj thjk; 
 MopNghw; gutpd; m/Nj gpj;jk; 
Kj;njhj;J epw;fpd; nkhopt njd; fgNk 
 mutpy; MopAk; Mopapy; muTk; 
mutpd; Kj;Jk; Mopapy; Kj;Jk;” 
  - rpj;j kUj;Jt Neha; ehly; Neha; Kjdhly; jpul;L 
b. Neerkkuri: 
“te;j ePh;f;fhp nail kzk; Eiu vQ;rnyd; 
 iwe;jpa Ysit aiwFJ KiwNa” 
     - rpj;j kUj;Jthq;f RUf;fk; 
Urine is examined for the following neerkkuri: 
 Niram   - Colour 
 Edai  - Specific Gravity 
 Manam - Smell 
 Nurai  - Frothy nature 
 Enjal  - Quantity of urine voided 
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In Azhal keel vaayu straw or hay coloured urine was noticed in Neerkkuri 
jpiz (Geographyical distribution): 
 FwpQ;rp : kayak; kiy rhh;e;j gFjpAk; 
 Ky;iy : fhLk; fhL rhh;e;j gFjpAk;. 
  “Ky;iy epyj;jika Ke;epiu NktpDky;...... 
  thjnkhop ahjjDz; kd;D kittopNeha;g; 
  Ngjnkhop ahjiwg; gpd;G” 
       - gjhh;j;j Fz rpe;jhkzp 
 kUjk;  : taYk; tay; rhh;e;j gFjpAk; 
 nea;jy; : flYk; fly; rhh;e;j gFjpAk; 
  “nea;jdpy NkYg;ig ePq;fh JwpDkJ ........... 
  kUq;Fliy kpf;fhf;Fk; : ty;YWg;ig tPf;Fk;> 
  fUq;Fliyf; fPopwf;Fq; fhz;” 
      - gjhh;j;j Fz rpe;jhkzp 
 ghiy : kzYk; kzy; rhh;e;j gFjpAk;. 
 Ky;iy kw;Wk; nea;jy; epyq;fspy; thj Neha;fs; ngUkstpy; Vw;gLk;. 
 ghiy epyk; thjk;> gpj;jk;> fgk; ,tw;why;> tpisfpd;w gpzpfl;F 
,Ug;gplk; MFk;. 
 
PARUVA KAALAM (Seasonal Variations): 
Siddhars have classified a year into six seasons each constituting two month 
Kaalam Kutram Suvai 
Kaar Kaalam 
Avani and Purattasi 
(Aug 16 - Oct 15) 
Vatham 
(Vetrunilai Valarchi) 
Pitham 
(Thanilai Valarchi) 
Enippu 
Pulipu 
Uppu 
Koothir Kaalam 
Iypassi and Karthigai 
(Oct 16 - Dec 15) 
Vatham (-) 
(Thanilai adaithal) 
Pitham 
(vetrunillai Valarchi) 
Enippu 
Kaippu 
Thuvaruppu 
Munpani Kaalam 
(Margazhi and thai) 
(Dec 16 - Feb 15) 
Pitham (-) 
Thanilai adaithal 
Enippu 
Pulippu 
Uppu 
Pinpani Kaalam 
(Massi and Panguni) 
(Feb 16 - Apr 15) 
Kapham 
(Thanilai valarchi) 
Enippu 
Pulippu 
Thuvaruppu 
 23 
 
VO cly; jhJf;fspd; Ma;T: 
t.vz;. 
cly; 
jhJf;fs; 
njhopy; 
moy;fPy; thAtpy; 
fhzg;gLtJ 
1 rhuk; 
cliyAk; kdijAk; 
Cf;fKwr; nra;tJ 
ghjpg;G 
(cly;Nrhh;T> kdNrhh;T) 
2 nre;ePh; 
mwpT> td;ik> xsp> 
nrUf;F ,itfis 
epiyf;f nra;tJ 
,ay;G 
3 Cz; 
clypd; cUtj;ij 
mikj;jYk;> vd;ig 
tsh;j;jYk; 
ghjpg;G (tPf;fk; 
fhzg;gly;> Cz; 
Fiwjy;) 
4 nfhOg;G 
cWg;Gfs; ,aq;f 
mtw;wpw;F nea;g;Giu 
Cl;LtJ 
ghjpg;G (fPy;fspy; nea;g;G 
gir Fiwjy;) 
5 vYk;G 
cly;  mirtpw;F 
mbg;gilahapUj;jy; 
ghjpg;G (vd;Ggyk; 
Fiwjy;) 
6 %is 
vd;Gf;Fs; epiwe;J 
td;ikAk;> nkd;ikAk; 
jUtJ 
ghjpg;G 
7 ntz;zPh; 
fU Njhw;wj;jpw;F 
Kjyha; epw;gJ 
,ay;G 
 
In Azhal Keel Vaayu, 
 Saaram, Kozhuppu, Oon and Enbu thathukkal are chiefly affected. 
1. rhuk; : cly;Nrhh;T> kdNrhh;T (Tiredness and pain in joints). 
2. nfhOg;G : fPy;fspy; nea;g;G gir Fiwjy; (Morning stiffness  occurs in affected 
knee joint) 
3. vYk;G : vd;Ggyk; Fiwjy; (Pain occurring in affected knee joints, crepitations 
Present) 
4. Cz; : tPf;fk; fhzg;gly;> Cz; Fiwjy; (Muscle wasting present) 
Kf;Fw;w NtWghL: 
 tspkpF tghd tpahd 
  thAf;f sjpf hpf;Fk; 
 ,skpf kyePh;f; fl;Lk; 
  ,ak;gpa tghdd; nra;Ak;  
       rghgjp ifNaL 
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thjk; njhopy; 
moy;fPy; thAtpy; 
ghjpf;fg;gl;l Fw;wk; 
gpuhzd; 
%r;R thq;fy; tpLjy; 
nra;Ak; 
,ay;G 
mghdd; fPo;Nehf;fp kyj;ijj; js;Sk; ghjpg;G (kyf;fl;L) 
tpahdd; 
cWg;Gfis ePl;b klf;f 
nra;Ak; 
ghjpg;G (fhy;fis ePl;b 
klf;Ftjpy; rpukk;) 
cjhdd; 
cztpd; rhuj;ij clypy; 
epWj;Jk; 
,ay;G 
rkhdd; kw;w thAf;fis rhpg;gLj;Jk; 
ghjpg;G (kw;w thAf;fs; 
ghjpg;G) 
ehfd; 
vy;yh fiyAk; fw;Fk; gb 
nra;jy; 
,ay;G 
$h;kd; 
fz;fis jpwf;fTk; %lTk; 
nra;Ak; 
,ay;G 
fpUfud; 
ehtpw; frpitAk; ehrpapw; 
frpitAk; cz;lhf;Fk; 
,ay;G 
Njtjj;jd; 
Nrhk;gy;> cly; Khpj;jy; 
cz;lhFk; 
,ay;G 
jdQ;nrad; 
,we;j gpd; %d;whk; ehs; 
jiyntbj;J ntspNaWk; 
- 
Neha;fzpg;G tpthjk; 
tspfPy; thA: 
 typf;Fj;jy; tPf;fq;fhZk; tha;j;njhz;il twl;rp fha;r;ry; 
 jiytyp khh;Jbg;Gj; jhq;nfhzh typ tPf;fe;jhd; 
 epyT fhq;fZf; Fwq;F ePL Njhs; Koq;iff; fhw;fhk; 
 kyf; Flw;fl;L Nth;it thjf;fPy; thA tpjhNk 
         - rghgjp 
ifNaL 
 jhq;f Kbahj typ> fhy;> tpuy;> Koq;fhy; %l;L> ,Lg;G %l;L> 
Koq;if %l;L> Njhs; %l;L Mfpa %l;L Mfpa %l;Lfspy; tPf;fk;> tha; 
twl;rp> Ruk;> jiytyp> glglg;G> kyr;rpf;fy;> tpah;j;jy; Mfpa 
FwpFzq;fisAilajhFk;. 
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Iaf;fPy; thA: 
 “fUjUq; fgf;fpy; thA fz;bbd; clypisf;Fk; 
 cUnkypthf;Fq; nfhs;Sk; cz;biar; RUf;F kpdge; 
 jUJapy; ePq;F Kl;bw; whq;nfhzh tYitahf;Fk; 
 ,UkNy tpf;fy; the;jp> Nrhig ghz;nlOg;Gk; ghNu” 
         - rghgjp 
ifNaL 
 %l;Lfspy; jhq;f Kbahj typ> cly; nkypT> grpapd;ik> tpf;fy;> 
the;jp> ghz;L Mfpa FwpFzq;fs; fhl;Lk; NehahFk;. 
tsp IafPy; thA: 
 “mitak; thjf; fgf;fPy; thAthd; typ kpFe;Nj 
 caq;F ePh; Nfhj;J fPy;fs; xhpapd; jiyNghw; fhZk; 
 eaq;nfhs;s Klf;fy; ePl;ly; ez;zplhnka;Aq;fhAk;> 
 kaf;FW Kwf;kpd;dhk; kd;dpa nehpf;fl;lhNk” 
         - rghgjp 
ifNaL 
gpj;jk; 
t.vz; gpj;jk; njhopy; 
moy;fPy; thAtpy; 
ghjpf;fg;gl;l Fw;wk; 
1 mdw;gpj;jk; 
cz;l czT nghUis 
nrhpf;Fk;gb nra;Ak; 
,ay;G 
2 ,uQ;rfk; nre;ePiu kpFjpgLj;Jk; ,ay;G 
3 rhjf gpj;jk; 
tpUg;gkhd njhopiy nra;J 
Kbf;Fk; 
ghjpg;G (njhopy; nra;a 
rpukk;) 
4 
MNyhrf 
gpj;jk; 
fz;fSf;F nghUis 
njhptpf;Fk; 
,ay;G 
5 
gpuhrf 
gpj;jk; 
NjhYf;F xypia nfhLf;Fk; ,ay;G 
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fgk; 
t.vz; fgk; njhopy; 
moy;fPy; thAtpy; 
ghjpf;fg;gl;l Fw;wk; 
1 mtyk;gfk; 
kw;w ehd;F Iaq;fSf;Fk; 
gw;W NfhlhapUf;Fk; 
ghjpg;G 
2 fpNyjfk; nrhpj;jy; ,ay;G 
3 Nghjfk; Ritia mjpfhpf;Fk; ,ay;G 
4 jw;gfk; fz;fSf;F Fsph;r;rp ,ay;G 
5 re;jpfk; 
fPy;fspy; epd;W ,aw;ifaha; 
vy;yhf; fPy;fisAk; 
xd;Nwhnlhd;W nghUj;jp jsu 
nra;Ak; 
ghjpg;G (fPy;fspy; ePl;b 
klf;f rpukk;). 
 
 %l;Lfspy; typ> tPf;fk;> fPy;fs; ehpapd; jiyNghy; fhzg;gLk;. ePl;l 
klf;f KbahJ. newp fl;bf; nfhs;Sk;. 
kUj;Jtk; 
 %d;wpnyhd;w ah;e;jij Kd;dwpe;J 
  Ke;jpajid nahopj;jpl kUe;jpL 
 jzpAk; Nehapd; je;jpukpJNt 
  Ngzpf; fzpj;jpbd; gpwtha; gpd;Fzk; 
     - Neha;ehly; Neha; Kjy; ehly; - gFjp-1 
 The treatment in Siddha system includes not only the removal of signs and 
symptoms of a disease but also in total uprootment of the diseases. 
This is achieved by normalizing the deranged Mukkutram there by retaining 
body’s natural health. The recurrence of the disease is prevented by the practice of 
Yoga and Pranayama. 
According to siddha system line of the treatment is divided in to three. 
Treatment is not only for perfect healing but also for the prevention and 
rejuvenation. The basic methods used in Siddha for treating disease are  
1. Kappu [Preventin] 
2. Neekam [Treatment] 
3. Niraivu [Restoration] 
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1. Kappu: [Prevention] 
The preventive Azhal keel vaayu is: 
1. Control the body weight by diet and exercise 
2. Modify the nature of work which gives stress to a particular joint. 
3.Avoid excess intake of sour, astringent and bitter tasted foods. 
In Azhal Keel Vayu the deranged Vatham and other toxic products of digestion and 
metabolism is brought to its normal state by purgation. (tpNurdk;) 
tpNurdj;jhy; thje;jhKk;: 
 15ml of vellai ennai is given with luke warm water at early morning (single 
dose) before starting the treatment with trial drug. 
a) INTERNAL MEDICINE: 
Kalinga Mathirai - 65mg in two divided dose/day after food. 
b) EXTERNAL MEDICINE: 
KODIVELI THYLAM - External application over the affected joints. 
c) EXTERNAL THERAPY (PATTRU): 
Apart from other department Sirappu Maruthuvam, department gives equal 
importance to External therapies in Siddha System of medicine. There are several 
complementary therapies followed in Siddha System of Medicine such as Kattu, 
Pattru, Nasiyam, Attaividal, Thokkanam, Ottradam, Varmam, Asanam, Vedha etc., 
The External therapies which are taken into account for this study is 
1. PATTRU: 
The drugs are heated with castor oil and apply as PATTRU. 
 1) Introduction 
 Puramaruthuvam Patru is one of the external therapies for instant remedy in 
treating headache, jaundice, sunstroke, abscess, fistula, hemorrhoids, chronic wounds, 
carbuncles, tumour, filarial swelling and lymphadenitis as explained by Therayar in his book 
Tharu. It is placed in second position at 32 external therapies series. 
 Patru is called as a poultice, which is soft and moist in nature. It is widely used to 
treat muscular sprain, arthritis, few surgical conditions, haemorrhoids, swellings and 
abscesses. 
 The semisolid paste is obtained from plant extracts or by grinding crude raw drugs is 
gently heated and applied as a thick paste over the affected region. 
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2) Definition 
 According to Therayar Patru is a method of applying fine powder or crude drugs 
grinded with an appropriate liquid as a semi solid poultice and warmed gently or boiled 
before applying it on the affected area. It is defined as one of a heat therapy by Therayar. It 
is generally used in the diseased conditions like swellings and abscesses. Eventhough Patru 
is not practiced under heat therapy, it is mandatory to warm the Patru before application 
for good prognosis. 
3) Purpose 
 To make the patient comfortable and fresh. 
 To improve circulation 
 To control inflammation of skin for redness, injuries, swelling, rashes or other infections 
 To prevent the blood clot 
 To cure peripheral neuritis 
 To bring cure for few surgical conditions 
 To incise and drain the abscesses 
 To remove or shring haemorrhoid mass 
 To reduce scrotal and hernia swellings  
 To minimize the topical antibiotics or steroids use 
4) Types  
 According to the physical nature it has wet and dry poultices. 
5) Therapeutic sources: 
 Plant parts such as leaves and barks 
 Egg yolk, Mother milk, Other milks, curd, urine 
 Inorganic distilled solutions 
6) Specifications 
 The treatment room has following specifications 
 10 x 10 feet room 
 Separate rooms for men and women 
 Screen 
 Steamer 
 Treatment chamber (Sitting or lying) 
 Wahsbasin 
 Bathroom 
 Floor mat 
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 Electric face steamer 
7) Eligible Criteria 
 Not eligible in 
 Cellulitis 
 Communicable diseases 
 Children below 3 years 
8) Articles Required 
 Patru is a fresh wet preparation and heated before use. Generally it has 2 steps. A 
fresh Patru is prepared using various drugs, gently warmed or boiled and finally applied on 
the affected areas. 
a) For preparation 
 Stone mortar and pestle for grinding  
 Steel mortar and rod for crushing  
 Stove or ovan 
 Mud or Iron deep frier 
 Knife 
 Wood and steel spoons 
b) For administration 
 A screen for privacy 
 Wash / Sponge cloths-2 
 Bath towel-1 
 A new set of clothing 
 Containers of sterile solution, hot and cold water 
 Wash basin 
 A tray containing gloves, gauze role cotton role, bath soap, surgical spirit, surgical knife, 
scissor, castor oil, gingelly oil, nail cutter, kidney tray, tissue paper, paper bag. 
 Waste bin 
 Surgical gloves 
9) Appropriate therapy timings 
 The ideal timings for applying Patru are in the morning for curing Vali related problems, 
noon for Azhal disorders and evening for Iyam disorders. 
10) Procedure 
 It has three steps 
 Procedure for preparation 
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 Procedure for administration 
 Procedure for removal 
a) Preparation 
 Purify (Suthi murai) the required drugs  
 Crush and grind with appropriate liquid  
 Store in a sterile container 
b) Administration 
 Assemble all the articles at therapeutic room bedside 
 Patient is to be asked to pass urine before beginning the procedure 
 Explain the procedure to the patient 
 Patient may be performed either in sitting or lying down (Prone, supine or lateral) positions. 
 Screen the patient for privacy 
 Cover the areas with apron or cloth except the affected area 
 Wash the site and clean dry with sterile cloth gently 
 Gently heat or boil the prepared Patru with the liquid  
 Apply the preparation on the site directly with a special care 
 Ask the patient to wait for 30-45 minutes without moving or shaking the site to prevent the 
fall down of the wet matter 
 The entire treatment of Patru is usually given for one time in a day at an interval of 3-7 days 
upto 3 Patru. 
c) Removal 
 Retain the Patru on the site for a period of 3 hours and upto 3 days. 
 Remove the Patru Kattu carefully making it wed by adding sterile  water and wash the site 
with lukewarm water or cold water 
 Wipe the place with dry cloth 
11) Care of Articles and Patients after Procedure 
 Dispose the skin debris and drug litter 
 Clean the table with soap or antiseptic solution 
 Autoclave the articles subjected to procedure 
 Wash your hands well 
 Remove the wastes as per BMW guidelines 
 Leave the patient comfortable 
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12) Indications 
  Abscess 
 Achilles tendonitis 
 Ano-rectal diseases 
 Arthritis 
 Bubo 
 Calcaneal spur 
 Carbuncle 
 Corn 
 Disc diseases 
 General chemical toxicity 
 Heavy metal toxicity 
 Lymphedema 
 Radiation and chemotherapy recovery 
 Relaxation and enjoyment 
 Scrotal swelling 
 Skin Diseases 
 Stress 
 Swelling  
 Wounds 
13) Contra-Indications 
 Deep ulcers with foreign bodies 
 Cellulitis 
 Gas gangrene 
14) Duration 
 3 hours to 7 days 
15) Shelf-life period 
 Not mentioned 
16) Cautions 
 Record if any abnormal changes have been observed in skin and bring it to the notice of 
Nursing therapist or doctor. 
 If burning pain, itching and discharge increased the Patru may be removed immediately 
17) Scientific validation: 
 The process during therapy 
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 Cleans the surface impurities 
 Protects the topical skin from toxins Removes the dead cells 
 Improves the nourishment to the adjacent cells 
 Posessess emollient, anti-microbial, anti-allergic, antiseptic, analgesic and anti inflammatory 
activities 
 Increases the peripheral circulation and healing process 
 Acts as chemical cautery to open and drain the abscesses 
 General systemic support by stimulating the lymphatic system 
 Comprehensive cleansing methodology 
18) Similar Therapies  
 Dermal Batch 
 Dermal Paste 
 Supra Dermal Pack 
 Topical application 
 Topical cataplasm 
 
njhf;fzk;: 
 njhf;fzk; = njhf;F + mzk; NjhNyhL mizj;J ifahsg;gLk; 
kUj;JtKiwahFk;. ,JNt kh;j;jdk; vdg;gLk;. tspahy; cz;lhff;$ba 
Neha;fs; vy;yhtw;iwAk; ePf;Ftjw;F gad;gLk;. 
 “kh;j;jd khfpa njhf;fzj; jpd;nray; tFg;NgNd - rjh 
 epe;jKk; thjk; gpzpj;j gpzg;igj; nrFg;NgNd 
 ky;yfuhd gplfh;if nad;fpw thshNy - gpzp 
 ty;ypia nka;apdpw; Nrjpg;guhe; jpwik thshNy 
 jpl;lypWf;fy; gpbj;jy; KWf;fy; if ijte;J - fuq;  
 fl;l nyOj;j tpOj;jy; ky;yhj;Jjy; ifte;J  
mire;jypy; nthd;gJ kj;jdj;jpd; jpw khdhYk;....” 
      - rpj;j mWit kUj;Jtk; 
njhf;fzj;jpd; nra;Kiw: 
 njhf;fzj;jpd; nra;KiwahdJ xd;gJ tifg;gLk; mit 
1. jl;Ljy; - Fj;Jjy; 
2. ,Wf;fy; 
3. gpbj;jy; 
4. KWf;fy; 
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5. iffl;ly; 
6. mOj;jy; 
7. ,Oj;jy; 
8. ky;yhj;Jjy; 
9. mirj;jy; 
njhf;fzj;jpd; gz;G 
 “njhf;fjzj;jp dhypuj;je; Njhy; Czpitfl;F 
 kpf;F rTf;fpaQ;r kPuDk; Ngh-nka;f;jpf 
 Gl;bAwf;fk; Gzh;r;rp apit fjpf;Fk; 
 gl;l miyr;ryWk; ghh;” 
       - rpj;jh; mWit kUj;Jtk; 
gad;fs;: 
 clypy; ghprpj;J tUk; fhw;wpdhy; cz;lhfpd;w Neha;f;F gpbj;jy; njhopy; 
kUe;jhFk;. 
 clk;gpYs;s ,uj;jk;> Njhy;> Cd; ,itfSf;F gyd; cz;lhFk;. J}f;ff; 
nfLjpahy; cz;lhFk; clw;Nrhh;T ePq;Fk;. 
 thjg;gpzpapdhy; vOe;jpUf;f KbahjtiuAk; vOe;J elf;fr; nra;Ak;. 
 gf;fthjk;> Klf;Fthjk; ,itfs; kpf;f ehshfpd; njhf;fzj;jpdhy; jPUk;. 
 NkYk; gpbg;G> RSf;F> cs;tPr;R> GwtPr;R> jDh;thA> ghhprthA ePq;Fk;. 
 Iae; jd;dpiyg;gl;L J}y NehAk;> kyl;L NehAk; Ngha;tpLk;. 
The above nine are the Thokkanam procedure in our system. In the In-
patient ward, the author had advised the Thokkanam methods for Chronic Azhal 
Keel Vayu patients. 
gj;jpak; (Dietary restrictions): 
 According to the nature of the illness and the ddrug administered, the 
patients were advised to follow certain special dietary method during the course of 
treatment. This special dietary regimen is said to be “Paithiyam”. 
 gj;jpaj;jpdhNy gyDz;lhFk; kUe;J 
 gj;jpaq;fs; Nghdhy; gyd; NghFk; - gj;jpaj;jpy;  
 gj;jpaNk ntw;wp jUk; gz;bjh;f;F Mjypdhw;  
 gj;jpaNk Af;jp nad;ghh;. 
        - Njiuah; ntz;gh ghly;-449 
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Advantages of the diet regimen: 
 Proper diet regimen enhances the bio-availability of the drug & Reduces harmful 
effect of the drug. 
 Sometimes food may antagonize the drug effect if diet regimen is not followed 
strictly. 
 Maintanance of the health 
“fLf ew;wpyj; njz;nza; $o;g;ghz;lq;fs; fliy 
tLt jhfpa njq;Fkh tUf;if ew;fhak; 
kbtp yhjnts;Ss;sp nfhs; Gifapiy kJngz; 
,lW ghfNyh lfj;jp ePf;fpylr; rghj;jpak;” 
      - rpj;j kUj;Jthq;f RUf;fk; 
fLF vs;nea;> Gsp> fy;ahz g+rzpf;fha;> fs;> fliy> Njq;fha;> 
khq;fha;> gyh> fhak;> nfhs;> Gifapiy> ghfy;> mfj;jp ,itfis 
kUe;Jz;Zk; fhyq;fspy; ePf;f Ntz;Lk;. 
GspJth; tpQ;Rk; fwpahy; g+hpf;Fk; thjk; 
Gspg;G> Jth;g;G RitAs;s czT tiffis ePf;f Ntz;Lk;. 
gj;jpaj;jpw;F MFk; nghUl;fs;: 
 fj;jphpg;gpQ;R> KUq;ifg;gpQ;R> mtiug;gpQ;R> thiog;gpQ;R> mj;jpg;gpQ;R> 
Rz;iltw;wy;> Kisf;fPiu> nghd;dhq;fhzp> Glyq;fha;> gPh;f;fq;fha;> mWfPiu 
nea;> ghy;> Nkhh;> nts;shl;L khkprk; Kjypad. 
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MODERN ASPECT 
ANATOMY OF KNEE: 
 Knee anatomy is about the structure of the knee – that is, the parts that 
makeup the knee. This article also tells you how a normal knee works and provides 
resources for problems of the knee joint or its parts including knee injuries. 
 Our knee is the most complicated and largest joint in our body. It‘s also the 
most vulnerable because it bears enormous weight and pressure loads while providing 
flexible movement. When we walk, our knees support 1.5 times our body weight; 
climbing stairs is about 3-4 times our body weight and squatting about 8 times. 
 The knee joint is a synovial joint which connects the femur, our thigh bone 
and longest bone in the body, to the tibia, our shinbone and second longest bone. 
There are two joints in the knee the tibiofemoral joint, which joins the tibia to the 
femur and the patellofemoral  joint which joins the kneecap to the femur. These two 
joints work together to form a modified hinge joint that allows the knee to bend and 
straighten, but also to rotate slightly and from side to side. 
 The knee is part of a chain that includes the pelvis, hip, and upper leg above, 
and the lower leg, ankle and foot below. All of these work together and depend on 
each other for function and movement. 
 The knee joint bears most of the weight of the body. When we‘re sitting, the 
tibia and femur barely touch; standing they lock together to form a stable unit. Let‘s 
look at a normal knee joint to understand how the parts (anatomy) work together 
(function) and how knee problems can occur. 
 
STRUCTURES OF THE KNEE: 
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 The main parts of the knee joint are bones, ligaments, tendons, cartilages and 
a joint capsule, all of which are made of collagen. Collagen is a fibrous tissue present 
throughout our body. As we age, collagen breaks down. 
 The adult skeleton is mainly made of bone and a little cartilage in places. 
Bone and cartilage are both connective tissues, with specialized cells called 
chondrocytes embedded in a gel-like matrix of collagen and elastin fibers. Cartilage 
can be hyaline, fibrocartilage and elastic and differ based on the proportions of 
collagen and elastin. Cartilage is a stiff but flexible tissue that is good with weight 
bearing which is why it is found in our joints. Cartilage has almost no blood vessels 
and is very bad at repairing itself. Bone is full of blood vessels and is very good at 
self repair. It is the high water content that makes cartilage flexible. 
Bones of the Knee 
 The bones give strength, stability and flexibility in the knee. Four bones make 
up the knee : 
 Tibia —commonly called the shin bone, runs from the knee to the ankle. The top of 
the tibia is made of two plateaus and a knuckle-like protuberance called the tibial 
tubercle. Attached to the top of the tibia on each side of the tibial plateau are two 
crescent-shaped shock-absorbing cartilages called menisci which help stabilize the 
knee. 
 Patella—the kneecap is a flat, triangular bone; the patella moves when the leg moves. 
It‘s function is to relieve friction between the bones and muscles when the knee is 
bent or straightened and to protect the knee joint. The kneecap glides along the 
bottom front surface of the femur between two protuberances called femoral 
condyles. These condyles form a groove called the patellofemoral groove. 
 Femur—commonly called the thigh bone; it‘s the largest, longest and strongest bone 
in the body. The round knobs at the end of the bone are called condyles. 
 Fibula—long, thin bone in the lower leg on the lateral side, and runs along side the 
tibia from the knee to the ankle. 
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 The knee works similarly to a rounded surface sitting atop a flat surface. The 
function of ligaments is to attach bones to bones and give strength and stability to the 
knee as the knee has very little stability. Ligaments are strong, tough bands that are 
not particularly flexible. Once stretched, they tend to stay stretched and if stretched 
too far, they snap. 
 Medial Collateral Ligament (tibial collateral ligament) – attaches the medial side of 
the femur to the medial side of the tibia and limits sideways motion of your knee. 
 Lateral Collateral Ligament (fibular collateral ligament) – attaches the lateral side 
of the femur to the lateral side of the fibula and limits sideways motion of your knee. 
 Anterior cruciate ligament – attaches the tibia and the femur in the center of your 
knee; it‘s located deep inside the knee and in front of the posterior cruciate ligament. 
It limits rotation and forward motion of the tibia. 
 Posterior cruciate ligament – is the strongest ligament and attaches the tibia and the 
femur; it‘s also deep inside the knee behind the anterior cruciate ligament. It limits 
the backwards motion of the knee. 
 Patellar ligament – attaches the kneecap to the tibia 
 The pair of collateral ligaments keep the knee from moving too far side-to-
side. The cruciate ligaments crisscross each other in the center of the knee. They 
allow the tibia to ―swing‖ back and forth under the femur without the tibia sliding too 
far forward or backward under the femur. Working together, the 4 ligaments are the 
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most important in structures in controlling stability of the knee. There is also a 
patellar ligament that attaches the kneecap to the tibia and aids in stability. A belt of 
fascia called the iliotibial band runs along the outside of the leg from the hip down to 
the knee and helps limit the lateral movement of the knee. 
Tendons in the Knee 
 Tendons are elastic tissues that technically part of the muscle and connect 
muscles to bones. Many of the tendons serve to stabilize the knee. There are two 
major tendons in the knee—the quadriceps and patellar. The quadriceps tendon 
connects the quadriceps muscles of the thigh to the kneecap and provides the power 
for straightening the knee. It also helps hold the patella in the patellofemoral groove 
in the femur. The patellar tendon connects the kneecap to the shinbone (tibia)—which 
means it‘s really a ligament. 
 
 The ends of bones that touch other bones—a joint—are covered with articular 
cartilage. It‘s gets its name ―articular‖ because when bones move against each other 
they are said to ―articulate.‖ Articular cartilage is a white, smooth, fibrous connective 
tissue that covers the ends of bones and protects the bones as the joint moves. It also 
allows the bones to move more freely against each other. The articular cartilages of 
the knee cover the ends of the femur, the top of the tibia and the back of the patella. 
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In the middle of the knee are menisci—disc shaped cushions that act as shock 
absorbers. 
 Medial meniscus 
o The medial meniscus is made of fibrous, crescent shaped cartilage and attached to the 
tibia, on the inside of the knee 
 Lateral meniscus 
o This is made of fibrous, crescent shaped cartilage and attached to the tibia, on the 
outside of the knee 
 
 Articular cartilage 
o Found on the ends of all bones in any joint—in the knee joint it covers the ends of the 
femur and tibia and the back of the patella. The articular cartilage is kept slippery by 
synovial fluid (which looks like egg white) made by the synovial membrane (joint 
lining). Since the cartilage is smooth and slippery, the bones move against each other 
easily and without pain. 
 In a healthy knee, the rubbery meniscus cartilage absorbs shock and the side forces 
placed on the knee. Together, the menisci sit on top of the tibia and help spread the 
weight bearing force over a larger area. Because the menisci are shaped like a shallow 
socket to accommodate the end of the femur, they help the ligaments in making the 
knee stable. Because the menisci help spread out the weight bearing across the joint, 
they keep the articular cartilage from wearing away at friction points. 
 The weight bearing bones in our body are usually protected with articular cartilage, 
which is a thin, tough, flexible, slippery surface which is lubricated by synovial fluid. 
The synovial fluid is both viscous and sticky lubricant. Synovial fluid and articular 
cartilage are a very slippery combination—3 times more slippery than skating on ice, 
4 to 10 times more slippery than a metal on plastic knee replacement. Synovial fluid 
is what allows us to flex our joints under great pressure without wear. 
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 The muscles in the leg keep the knee stable, well aligned and moving—the 
quadriceps (thigh) and hamstrings. There are two main muscle groups—the 
quadriceps and hamstrings. The quadriceps are a collection of 4 muscles on the front 
of the thigh and are responsible for straightening the knee by bringing a bent knee to a 
straight position. The hamstrings is a group of 3 muscles on the back of the thigh and 
control the knee moving from a straight position to a bent position. 
The Joint Capsule 
 The capsule is a thick, fibrous structure that wraps around the knee joint. 
Inside the capsule is the synovial membrane which is lined by the synovium, a soft 
tissue that secretes synovial fluid when it gets inflamed and provides lubrication for 
the knee. 
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Bursae around the knee: 
There are about 13 bursae around the knee. 
 Anterior - fourbursae. 
 Lateral - fourbursae. 
 Medial - five bursae. 
Anterior bursae: 
1. Subcutaneous prepatellar busa 
2. Subcutaneous infrapatellar bursa 
3. Deep infrapatellar bursa 
4. Supra patellar bursa. 
Lateral bursae: 
1. Bursa deep to lateral head of gastrocnemius 
2. Bursa between fibular collateral ligament and biceps femoris. 
3. Bursa between fibular collateral lingament and tendon of popliteus. 
4. Bursa between tendon of popliteus and lateral condyle of tibia. 
5. Medial bursae: 
Bursae around the knee: 
There are about 13 bursae around the knee.  
 Anterior - fourbursae. 
 Lateral - fourbursae. 
 Medial - fivebursae. 
Anterior bursae: 
1 Subcutaneous prepatellar bursa 
2 Subcutaneous infrapatellar bursa 
3 Deep infrapatellar bursa 
4 Supra patellar bursa 
Lateral bursae: 
1 Bursa deep to lateral head of gastrocnemius. 
2 Bursa between fibular collateral ligament and biceps lemons. 
3 Bursa between fibular collateral lingament and tendon of popliteus. 
4 Bursa between tendon of popliteus and lateral condyle of tibia. 
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Medial bursae: 
1. Bursa deep to medial head of gastrocnemius 
2. Bursa deep to tibial collateral ligament 
3. Ansarine bursa. 
4. Semimembranosus bursa 
5. Bursa between the tendons of semimembranosus and semitendinosus. 
 
 
Relations of Knee joint 
Anteriorly: 
1. Anterior bursae 
2. Ligamentum patellae. 
3. Patellar plexus of nerves Posteriorly 
A. At the middle: 
1. popliteal vessels 
2. Tibial nerve 
3. Middle genicular vessels and nerve 
B. Posterio laterally: 
1. Lateral head of gastrocnemius 
2. Plantaris 
3. Common peroneal nerve. 
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C. Posterio medially: 
1. Medial head of gastrocnemius 
2. Semitendinosus 
3. Semimembranosus 
4. Gracitis 
5. Popliteus 
Medially: 
1. Sartorius, gracilis and semitendinosus 
2. Great saphenous vein with saphenous nerve and vessels 
3. Semimembranosus 
4. Inferior medial genicular vessels and nerve  
Laterally: 
1. Biceps femoris 
2. Tendon of popliteus 
3. Inferior lateral genicular vessels and nerve. 
 
Blood supply: 
Knee joint is supplied by 
1. Genicular branches of popliteal artery 
2. Descending branch of lateral circumflex femoral artery 
3. Two recurrent branches of anterior tibial artery. 
4. Circumflex fibular branch of posterior tibial artery.
Nerve supply: 
1. Femoral nerve, through its branchesto vasti. 
2. Sciatic nerve, throughthe genicular branches of tibial and common peroneal nerve. 
3. Obturator nerve, through its posterior division 
Movements of knee joint 
Active movements at the knee are 
1. Flexion 
2. Extension 
3. Medial rotation 
4. Lateral Rotation 
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 Flexion and extension are the chief movements of much greater range than 
rotations. These are permitted in the upper compartment of the joint, above the 
menisci. Flexion and extension take place in transverse axis. During extension the 
axis moves upwards and forwards. During flexion the axis moves downwards and 
backwards. 
 Rotatory movements at the knee are of a smaller range than that of flexion 
and extension. Rotations take place around a vertical axis and are permitted in the 
lower compartment of the joint, below the menisci. 
Movements of the knee joint:Flexion and extention are the main knee 
movements,some rotations occur when the knee flexed. 
 
 
Locking and unlocking of the knee (conjunct rotations): Locking: 
 It is defined as medial rotation of femur on tibia during terminal stages of 
extension of the knee, when feet are supporting the body weight, when knee is 
locked, it is completely rigid and all ligaments of the joint are taut.- 
 
Movement Degrees possible 
Primary muscle 
producing 
movement 
secondary 
muscle 
producing 
movement 
Extension 0 
Quadriceps 
femoris 
Tensor 
fascialata 
;
 Flexion 
 
120 degree-hip ext 140 
degree-hip flexed 160 
degree- passively 
Hamstrings 
Short head of 
biceps 
Gracilis 
Sartorius 
Popliteus 
Medial rotation 
10 degree with knee 
flexed 
5 decree with knee 
extended 
Semimembranosus 
Semitendinosus 
popiiteous 
Gracilis 
Sartonous 
Lateral rotation 30 decree Biceps fcraons  
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UnLocking: 
 It is defined as lateral rotation of femur on tibia during initial stages of flexion 
of the knee, when feet are supporting the body weight. It is brought about by 
popliteus. It can be further flexed by the hamstrings. 
Adjunct rotations: (or) Independent active rotations: 
 It can occur only in flexed knee. They contribute to the twisting movements of 
the body when feet are fixed. 
Accessory or passive movement: 
It can be performed in a partially flexed knee. These movements include 
1. A wider range of rotation 
2. Anteroposterior gliding of tibia on femur. 
3. Some adduction and abduction. 
4. Some separation of tibia from femur.
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 Osteoarthritis 
Introduction 
 Osteoarthritis (OA), also know as degenersative joint disease. In Greekwood 
osteon for bone, arthron for joint & the suffix It’s for inflamnation. Osteoarthritis 
refers to a clinical syndrome of joint pain accompanied by varying degrees of 
functional limitation and reduced quality of life. It is the most common form of 
arthritis, and one of the leading causes of pain and disability worldwide. The most 
commonly affected peripheral joints are the knees, hips and small hand joints. Pain, 
reduced function and effects on a person's ability to carry out their day-to-day 
activities can be important consequences of osteoarthritis. Pain in itself is also a 
complex biopsychosocial issue, related in part to a person's expectations and self- 
efficacy (that is, their belief in their ability to complete tasks and reach goals), and is 
associated with changes in mood, sleep and coping abilities. There is often a poor 
link between changes visible on an X-ray and symptoms of osteoarthritis, minimal 
changes can be associated with a lot of pain, or modest structural changes to joints 
can occur with minimal accompanying symptoms. Contrary to popular belief, 
osteoarthritis is not caused by ageing and does not necessarily deteriorate. There 
are a number of management and treatment options (both pharmacological and 
non-pharmacological), which this guideline addresses and which represent effective 
interventions for controlling symptoms and improving function. 
Osteoarthritis is characterised pathologically by localised loss of cartilage, 
remodelling of adjacent bone and associated inflammation. A variety of traumas 
may trigger the need for a joint to repair itself. Osteoarthritis includes a slow but 
efficient repair process that often compensates for the initial trauma, resulting in a 
structurally altered but symptom-free joint. In some people, because of either 
overwhelming trauma or compromised repair, the process cannot compensate, 
resulting in eventual presentation with symptomatic osteoarthritis; this might be 
thought of as ’joint failure'. This in part explains the extreme variability in clinical 
presentation and outcome that can be observed between people, and also at 
different joints in the same person. 
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  There are limitations to the published evidence on treating osteoarthritis. 
Most studies have focused on knee osteoarthritis, and are often of short duration 
using single therapies. Although most trials have looked at single joint involvement, 
in many people ha \ e pam in more tnar. one joint, which may alter the 
effectiveness of interventions. 
Definition 
 Osteoarthritis is a chronic progressive degenegative disease affecting mainly 
the articular cartilage of the big weight beging joints of the body mainly in the aged 
individuals. It is the most common form of arthrities. 
Epidemiology 
 Knee OA principally occur before the age of 50 years. The occurrence of 
clinically apparent knee osteoartritis in 30% in the population older than 75 years. OA 
of at least one joint occurs in 80% of this population. 
 The fact that the incidence of OA increase significantly with age has led to the 
erroneous ending that OA is simply or age-related degenerative condition. The 
occurrence of OA increases with age because of ligamentous laxity. The frequency of 
OA is higher in women than in men.particularly after the age of 50 years 
Etidogy 
 Gge : Above 60 yrs. 
 Heredity 
 Abnormal stress & strein on the joints 
 Obesity 
 Hypemobility 
 Orthopedie deformities 
 Endolrine disorder like diabetes meiiitus. aeromegaly & hyperparathyroidium 
sensory newropathias. 
 Geography In a review of Osteoarthritis in 6 population living in different 
climates, as determined by latitude. 
 Older age. The risk of osteoarthritis increases with age. 
Sex. Women are more likely to develop osteoarthritis, though it isn't clear why. 
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  Obesity. Carrying extra body weight contributes to osteoarthritis in several 
ways. It puts added stress on weight-bearing joints, such as your hips and knees. In 
addition, fat tissue produces proteins that may cause harmful inflammation in and 
around your joints. 
 Joint injuries. Injuries, such as those that occur when playing sports or from 
an accident, may increase the risk of osteoarthritis. 
 Certain occupations. If your job includes tasks that place repetitive stress on 
a particular joint, that joint may eventually develop osteoarthritis. 
 Genetics. Some people inherit a tendency to develop osteoarthritis. 
 Bone deformities. Some people are bom with malformed joints or defective 
cartilage, which can increase the risk of osteoarthritis. 
Metabolic factors There has been some evidence for a link between Diabetes and 
Osteo arthritis, possibly through elevated growth hormone levels that alter cartilage 
metabolism and increase bone density 
 Mechanical factors It has been long considered that mechanical stress, such 
as single impact stress, gross anatomical damage 
 Other diseases. Having diabetes or other rheumatic diseases such as gout 
and rheumatoid arthritis can increase your risk of osteoarthritis. 
Remember the Risk factors : - 
 O - Oberity 
 S - Sensility or old age 
 T-Traum 
 E-Emotional stress 
 O-Osteoporosis 
 A - Alcrhot 
 R - Rigorous Lifestyle 
 T-Toxing professions 
 H - Hormondimbolox 
 R - Reyptitive injuries 
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  I - Indian cufard habits 
 T - Axing sports 
 I - Improper postural Labrs 
 S - Smoking
SITES: 
Common sites of primary osteoarthritis: 
 Apophyseal joint of the cervical spine. 
 Thoraco lumbar spine. 
 First carpometacarpal joint. 
 Distal interphalangeal joint. 
 Patella femoral joint. 
 Tibio femoral joint. 
 First metatarsophalangeal joint. 
Intermediate sites: 
 Acromio clavicular joint 
 Hip joint 
Uncommon sites: 
 Shoulder joint 
 Elbow joint 
 Wrist joint 
 Ankle joint 
CLASSIFICATIONS: 
It could be divided into 2 types  
1. Primary or idiopathic osteoarthritis. 
2. Secondary osteoarthritis. 
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 PRIMARY OSTEOARTHRITIS 
 Usually limited to one or a small number of joints. 
 No exact inflammatory or metabolic condition known to be associated with 
arthritis is present. 
 No history of definite injury or trauma. 
SECONDARY OSTEOARTHRITIS 
 May be limited to a small number of joints in injury linked or may be in joints 
throughout. 
 Condition that cause damage to cartilage are present, such as - 
 Inherited disease of iron, calcium or copper storage. Neurologic disorder that 
result in the loss of nerve function. 
 Congenital disease that cause an disparity in the joints 
 History of injury to joints, such as fractures and tears or history of trauma. 
PATHOLOGY:- 
 The pathology of OA provides evidence, of the panarticular involvement of 
disease. 
After an injury to cartilage, Chondrocyles undergo mitosis and clustering. 
 The metabolic activity of these chondrocyte clusters is high, the net effect of 
this activity is to promote rroteogly can depletion in the matrix surrounding the 
condrocytcs. 
 This disease develops, collagen matrix becomes damaged, the nagative 
charges of proteoglycans get exposed, and cartilage swells from ionic attraction to 
water molecules. 
 Chondrocytes at the basal level of cartilage undergo opoptosis. 
 In healthy Joints, the synoviom consist of a single discontinuous layer filled 
with fat and containing two types of cells, macropheges and fibroblasts. 
 But in OA, it can sometimes edematous and inflamed 
 There is migration of macrophages from the periphery into the tissue, and 
cells living the synovium proliferate. 
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  Enz\raes secreated by the Synovium digest cartilage matrix that has been 
shea led from the surface of the cartilage. 
 Bone remodding is a prominent feature of hand OA. 
 Basically, calcium Phosphate, calgium purophosphate dehydrate crystals are 
present microscopically in most joints with end-stage OA. 
Pathological Changes in Osteoarthirits 
The disease process usually begins in the antesomedial compartment of 
joint. 
Transformation of Normal cartilage to Aging cartilage 
 Several structural and biochemical changes involving the collagenous 
components of the matrix occur during aging. These changes alter biochemical 
properties of the cartilage that are essential for the distribution of forces in the weight 
bearing zone. 
Articular cartilage - Changes 
 The regressive changes are most marked in the weight bearing regions of articular 
cartilages. 
 Initially there is loss of cartilaginous matrix(proteoglycans) resulting in progressive 
loss of normal metachromasia. 
 Focal loss of chondrocytes and at other places, proliferation of chondrocytes forming 
clusters 
 Further progression of the process cause loosening, flaking and Assuring of the 
articlular cartilage resulting in breaking off of pieces of cartilage thus 'exposing 
subchondral bone'. 
 Radiologically this progressive loss of cartilage is apparent as ‘narrowed joint space*. 
 Molecular mechanism of damage to cartilage in osteoarthritis appears to be the 
breakdown of collagen type II probably by 1L-1, TNF and nitric oxide. 
II. Changes in the bone 
 The denuded subchondral bone appears like ‘polished ivory'. 
 There is death of superficial osteocytes and increased osteoclastic activity causing 
rarefaction. ‘Microcyst formation and occasionally microfractures of the subjacent 
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 bone’. 
 Changes result in remodelling of bone and changes in the shape of the joint surface 
leading to the flattening and ‘mushroom like appearance’ of the articular end of the 
bone. 
 The margins of the joints respond to cartilage damage by ‘osteophyte or spur 
formation’. 
 These osteophytes are cartilaginous outgrowths at the joints margins, which later 
gets ossified. 
 Osteophytes give the appearance of lipping of the affected joint 
 Loosened and fragmented detached osteophytes may form free “joint mice or 
loose bodies” 
III Changes in the synovium 
 Initially there are no pathologic changes in the synovium. 
 But in advanced cases there is low grade chronic synovitis and villous hypertrophy. 
 There may be some amount of synovium effusion associated with chrome synovitis. 
 Glycosaminoglycans are modified qualitatively ; they become shorter as the 
cartilage ages. The concentration of type 6 keratan sulphate increases during aging, 
to the detriment of type 4 keratan sulphate. 
 These quantitative and qualitative changes in proteoglycan reduce the 
capacity of the molecules to retain water. Thus aging cartilage contains less water 
which alters the biochemical properties of the cartilage. Fissures that develop in 
cartilage during aging are mainly due to stress fractures of the collagen network.
52 
 TABLE 173.3 STAGING OF OSTEOPHYTE DEVELOPMENT ACCORDING 
TO GELSE AND AIGNER (2003) 
 
Stage 0 
(normal) 
Normal Periosteum 
Stage I Slight thickening of the periosteum 
incipient formation of fibro cartilage (some round cells, some 
metachromatic tissue staining of the extra cellular matrix) 
No/slight active bone formation 
Molecular markers: 
 Focal collagen type II expression 
 No collagen type X 
State II Pronounced thickening of the eriosteal layers 
Well-established formation of fibro cartilage (many round 
cells, strong metachromatic tissue staining of the extra cellular 
matrix) Some / moderate bone formation 
Molecular markers: 
 Distinct collagen type II expression 
 No collagen type X 
Stage III Pronounced thickening of the periosteal layers 
Well - established formation of fibro cartilage (many round 
cells, strong metachromatic tissue staining of the extra cellular 
matrix, formation of lacunae) 
Strong active bone formation 
Molecular markers: 
 Distinct follagen type II expression 
 Collagen type X expression in basal areas 
 Collagen type VI: intermixed with collagen types I, 
III,  and V in the inter cellular matrix. 
Stage IV Significant thickening of the periosteal layer 
Apparent formation of fibro cartilage with partial 
hyalinization of the extra cellular matrix (chondrocyte-like 
cells in lacunae, strong metachromatic tissue staining of the 
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 extra cellular matrix)  
Some active bone formation 
Molecular markers: 
 Ubiquitous presence of collagen type II 
 Collagen type X in basal areas 
 Collagen type VI: mostly per cellular 
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TYPING, STAGING, AND GRADING OF JOINT CARTILAGE 
ALTERATIONS IN OSTEOARTHRITIS 
 Overall, the classification of OA cartilage degeneration is rather complex 
because all patients present with at least to some extent dif-ferent histories, 
symptoms, and morphologic changes. Common to all of them is some sort of 
structural joint (cartilage) damage, pain, and limitation in joint movement. 
 Obviously, many other tissues apart from the articular cartilage are involved 
in this process, but, traditionally, the cartilage has been used to score OA severity. In 
general, the process of joint destruction can always be evaluated for the 
pathogenesis for its extent and for the degree of the most extensive focal damage. 
"'I\ping" is mostly related to “primary" and “sec-ondary" OA. Primary OA is most 
frequently observed. Whereas the addition “primary" implies that there is no 
obvious cause, still minor preexisting conditions also exist in this condition . The 
major causes leading to secondary OA joint degeneration are listed “Grading” and 
“staging” have been much more under debate, also regarding the basic meaning of 
botii words: “grading” should refer to the evaluation of histologic changes at one 
site of joint destruction, whereas “staging” should refer to the overall disease 
process. Both represent an attempt to score processes relevant to the disease. 
 However, clearly some of the subcategories of the Mankin score do not 
belong to primary cartilage degeneration but describe features observed in 
secondary cartilage formation and should be excluded in future scoring attempts. 
The Outerbridge system was primarily described for the patella but later successfully 
applied to other joints. Whereas Mankin addresses the piece of cartilage under the 
microscope, the staging systems look at the whole joint surface mostly 
macroscopicallv. At the site of the highest cartilage damage, grading and staging are 
closely con-elated. Clearly, a pure macroscopic staging system is too rough for 
scientific puiposes and. thus, a new staging system has been proposed by Pritzker 
and colleagues that combines histopatho-logic grading parameters with the 
extension of the lesions. Doubtless, along with new scientific insights and more 
extensive and specified medical options, we will need more elaborated and 
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validated “grading” and “scoring” systems, and this will be a major task in the near 
future. 
Of crucial importance will be the use of a defined and unified nomenclature 
to make studies, descriptions, and results comparable, whereas at the moment 
many similar-sounding terms are used for partly different phenomena and 
differently sounding words for the same 
TYPING AND GRADING OF SYNOVIAL MEMBRANE ALTERATIONS IN 
OSTEOARTHRITIS 
 Clinically relevant OA joint disease is invariably associated with some sort of 
synovial pathology. This reflects the notion that there is a direct relation between 
clinical symptoms and the synovial reaction in OA and most likely these changes in 
the synovial membrane are at least partly involved in the progression of the disease. 
In OA synovial speci-mens, in principle, four different types of OA synoviopathies are 
found: hyperplastic, inflammatory, fibrotic, and detritus-rich synoviopathy. 
 Detritus-rich synovitis, which is found in end-stage OA disease, is due to 
abundant macromolecular cartilage and bone detritus (i.e., bone and cartilage 
fragments attached to or incorporated into the synovial membrane; i) in addition 
to abundant molecular debris that is not visible microscopically. Besides the debris, 
a significant amount of fibrinous exudate is found at the surface of the synovial 
membrane. This exudate may be combined with incorporated fibrin, reflecting 
longer ongoing fibrinous exudation already being organized. Detritus-rich 
synoviopathy usually contains a minor inflammatory cell infiltrate consisting of 
lymphocytes and granulocytes as well as some foreign-body giant cells. 
 Another form of OA synoviopathy found in late-stage disease, fibrotic OA 
synoviopathy is mainly characterized by the shortening and thickening of the joint 
capsule, which is partly responsible for some symptoms, m particular joint stiffness, 
seen in OA patients. 
 The most interesting of the OA synoviopathies m terms of patho-genesis is 
the inflammatory OA synoviopathy, which displays moder-ately extensive 
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lymphocytic infiltrates. It is intriguing to speculate whether this condition reflects 
some kind of autoimmune aspcct that msv he occurring, at least in ui!> mjosci 01 '.’A 
patients. Interestingly, the lymphocytic infiltrate in the subsynovial stroma appears 
to correlate directly with interleukin (IL)-ip in the synovial fluid as well as matrix 
metalloproteinase-1 (MMP-1) expression by synoviocytes, suggesting a direct 
stimulatory role of the inflammatory cells on the activity of the synovial lining cells. 
In any case, the pres-ence of inflammation in a significant portion of OA patients 
clearly points to the option of anti-inflammatory therapy at least for some subsets of 
OA patients.  In early OA, mostly hyperplastic OA synoviopathy is found . This 
pattern shows only moderate synovial hyperplasia with or without cellular activation 
but .without significant capsular fibrosis or thickening and without significant 
inflammatory infiltrates or mac-romolecular detritus. Overall, three forms of 
alterations of the synovial surface can be observed: 
 Increased cytoplasmic volume of the usually flat synovial lining cells. These 
cells may even become cuboidal or even cylindrical, suggesting that they have been 
activated in some way. 
 The under normal conditions single (flat) cell layer of synovial lining cells can 
proliferate to form as many as five cell layers 
 The whole synovial surface, including the underlying stroma, can become 
hyperplastic and form the classic synovial villi. 
 Synovial hyperplasia per se can be found in all forms of OA synovi-opathy 
and in chronic synovitis. Thus, villous hyperplasia is largely a non-specific feature of 
chronic synovial alteration and activation. 
 So far, no well-established scoring system is available for human OA 
synoviopathy. Recently, a simple scoring system was proposed by Krenn and 
colleagues to separate inflammatory and non-inflammatory synovial alterations 
mainly based on the intensity of inflammatory infiltrates, synovial and stromal 
activation. In 2002 we proposed a scoring system specifically for OA synoviopathy 
basically dividing the OA-associated synoviopathies into four categories 
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hypertrophic, fibrotic, inflammatory, and detritus-rich. These can always be 
subdivided into mild, moderate, and strong depending on the intensity of changes 
present.5 This presumably reflects the different roles of OA synoviopathy and its 
implications for the clinical picture. Whatev er scoring system is used, importantly 
one should average the changes present in the overall joint and not just rely on one 
particular region, because synovial changes are notoriously heterogenous w ithin 
affected joints. 
EVALUATION OF REGENERATIVE CARTILAGE FORMATION IN 
OSTEOARTHRITIC JOINTS (CHONDRO-OSTEOPHYTE FORMATION) 
 Central for the basic understanding of osteophytic tissue is the analysis of the 
developmental steps during osteophyte formation. Thus, although it is clear that 
osteophyte development is a continuous process and many osteophytes show 
different steps in various portions at the time one ran nefine hnsR- stei'K based 
on the cellular phenotype and the matrix composition of the predominating tissue 
Initially, mesenchymal precursor cells derived either from periosteum or synovium 
initiate chondrogenic differentiation. This results in fibrocartilage composed of both 
fibrous and cartilaginous matrix components. In early osteophytes, endochondral 
ossification is initiated. The deepest cell layer becomes hypertrophic and resembles 
very much the lowest cells found in the fetal growth plate. Mature osteophytes are 
characterized by the predominance of a hyaline-cartilage-like extracellular matrix. At 
a first glance, mature osteophytes can, macroscopically and histologically, easily be 
mistaken for original articular cartilage. Although hyaline zones in osteophytes 
resemble articular cartilage in terms of structural composition, there are, 
nevertheless, certain differences such as a more random cellular arrangement, the 
lack of a distinct tidemark, and a missing linear subchondral bone plate. 
 Understanding osteophyte formation and classifying its maturation stage is 
on the one hand interesting per se for understanding changes going on in the 
chondro- osseous department in OA joints, but addi-tionally osteophyte formation 
represents an interesting in-vivo model system to understand and evaluate 
processes occurring after many modem cartilage repair strategies. 
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 Although only a few millimeters thick at most, articular cartilage has an 
elaborate internal organization.lt has 4 Zones. 
 The superficial zone 
 The intermediate zone 
 The deep zone 
 The calcified cartilage zone. 
Within zones, three regions or compartments are seen 
 The pericellular region 
 The territorial region and 
 The interterritorial region. 
CARTILAGE ZONES. 
 Cartilage zones differ in matrix composition, water concentration, collagen 
fibril orientation and cell alignment, and morphology 
Superficial zone. 
 It is the smallest cartilage zone and it forms the joint surface. 
 Deep to this layer, elongated flattened chondrocytes are seen  
Middle zone. 
 The middle of transition zone has numerous times the volume of the 
superficial zone. Its more spherical cells contain greater volumes of endoplasmic 
reticulum. Golgi membranes, mitochondria, and glycogen 
Deep zone: 
 The cells of the deep of radial zone look like the spherical cells of the 
transitional zone but tend to line up themselves in columns. This /one lias Hie 
largest collagen fibrils, 
Calcified Cartilage Zone. 
 The thin calcified cartilage zone separates the hyaline cartilage from the stiffer 
Subchondral bone. 
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Matrix Regions. 
 Matrix regions differ in their proximity to chondrocytes, collagen content, 
collagen fibril diameter, collagen fibril orientation, and proteoglycan and 
noncollagenous protein content and organization. 
Growth Cartilage: 
 Bones elongate by growth of the cartilage forming the physes of growth 
plates. The complex structure of the physes makes it possible for them to produce 
precisely directed longitudinal bone growth. 
 The growth cartilages increase their volume and therefore bone length by 
synthesizing new matrices and by cell swelling. The organization of the growth 
cartilage matrix and the surrounding fibrous tissue directs the rising volume of cells 
and matrices, so that it produces longitudinal bone growth. 
 In the region of the growth cartilage nearest to the metaphysic, the 
longitudinal cartilage septae of the growth cartilage mineralize, and in the 
metaphysis, osteoblasts above the mineralized cartilage bars with new woven bone. 
Osteoclasts then resorb the w oven bone and calcified cartilage and osteoblasts form 
lamellar bone to complete the substitute of cartilage by mature bone. 
Clinical future 
Pain.  Knee joint may hurt during or after movement. 
Tenderness. Knee joint may feel tender when you apply light pressure to it. 
Stiffness. Joint stiffness may be most noticeable when you wake up in the 
morning or after a period of inactivity 
Loss of flexibility.  Knee may not be able to move the joint through its full  
  range of motion. 
Grating sensation.  Knee may hear or feel a grating sensation when   
 you use joint. 
Bone spurs.   These extra bits of bone, which feel like hard lumps,  
   may form around the affected joint. 
On Examination 
Tenderness on the joint 
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Crepitas on moving the joint 
Osteophyte Jormation. 
Defomity - Varus of the 
Effusion - Rare & Transient 
Termind limitation of joint movement 
Subluxation detected on ligamcat testing 
Wasting of quedriceps jemon's muscle. 
Me Murray’s test 
 This test checks for meniscal tears and other internal derangement in the knee. 
Thessaly’s test 
 This functionally tests menisaus tears in the standing position. Since bending 
and twisting movements while weight bearing often reproduce pain exacerbating 
movements. 
Pressure. 
 Such structures include the joint surfeices of the knee cap the femur, the tipia, 
and the muscles and tendors around the knee. 
Effusion test 
patellar tap - helpful test for large effusious 
Bailottement - defined as a palpatory techinique for detecting (or) investigative a 
flouting object in the body. 
Bulge sign - test for smaller effusions. 
Auterior Drawer 
 The outerior Drawer test examines for any tearing (or) loxity of tue anterior 
cruciate ligaments 
Valus test 
 The valgus stress text elelcs for medial joint laxity which usually represents an 
injury to the medical collateir ligaments. 
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Varus test 
 The various test stress test checks for joint laxity on the outside of tue knee 
which usually reponesent an tujary to the lateral collateral ligaments 
 Effusion (3): patellar tap test (ballottement test) (1): Squeeze any excess 
synovial fluid out of the suprapatellar pouch with the index and thumb, slid firmly 
distallv from a point about 15 cm above the knee to the level of the upper border of 
the patella. This will also ‘float’ the patella away from the femoral condyles. 
 Effusion (4): patellar tap test (2): Place the tips of the thumb and three 
fingers, of the free hand squarely on the patella, and it quickly downwards towards 
the femur. A click as the patella strikes the condyles indicates the presence of 
effusion. Note that if the patella is not properly steadied as described it will tilt, 
giving a false negative. Note too that if the effusion is slight or tense, the tap test m 
.\bcjicgatire. 
 Effusion (5): fluid displacement test (1): Small effusions may be detected 
by this manoeuvre. Evacuate the suprapatellar pouch as in the patellar tap test 
before. 
 Effusion (6): fluid displacement test (2): Stroke the medial side of the joint 
to displace any excess fluid in the main joint cavity to the lateral side of the joint. 
 Effusion (7): fluid displacement test (3): Now stroke the lateral side of the 
joint while watching the medial side closely. Any excess fluid present will be seen to 
move across the joint and distend the medial side. This test will be negative if the 
effusion is gross and tense. 
 Synovial membrane: Pickup the skin and the relaxed quadriceps tendon to 
assess the thickness of the synovial membrane in the suprapatellar pouch. The 
synovial membrane is thickned in inflammatory conditions, e.g. rheumatoid 
arthiritis. and in vilonodular synovitis. 
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OA Complication 
 Capsular herniation OA of the knee is sometimes associated with a marked 
effusion and herniation of the posterior capsule (Baker‘s cyst) 
 Cartilage and boue fragments may give rise to loose bodies, resulting in 
episode of locking 
 Rotator Cuf dysfunction OA of the acromio clavicular join may cause rotator 
culf impingemtents tendonitis (or) cuff puncture. 
 Spinal Stenosis Long standing hypertrophic OA of the lumbar apophyseal 
joints may rise to acquired spinal stenosis 
 Spondylolisthesis in patients over 60 years of age, destructive OA (of the 
apophyseral joints may result in server segmensal instability and spondylolisthesis 
(degenerative spondylolisthesis) which almost always occuse at 
Differential Diagonisis  
Avascular necrosis: 
 Idiopathic necrosis causes joint pain and local effusion. Early diagnosis is 
made by MRI. Once bone destruction occurs the X-ray changes can be mistaken for 
those of Osteoarthritis.The cardinal characteristic features is that in osteonecrosis is 
the ‗joint space' (articular cartilage) is preserved in face of progressive bone collapse 
and deformity. 
 
Rheumatoid arthrities 
 A number of condition may mimic osteoartharities in knee. They are 1. 
Rheumatoid arthrities. It is an disorders. It commonly affects women between 
24- 40 years. Characteristically it is bilaterally symmetrical Initially it affects 
the small joints of hand (or) foot and may spread to large joints painful 
swelling of the joints with stiffness and deformity may occurs. Muscle 
spasam and muscle wasting maybe prctent. Restriction of movements is 
00111111011. X -ray shows decalcifi cation and dcminished joint space may 
be seen. RA factor is mosty positive.  
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Tuberculous Arthritis 
 Tuberculosis of the knee more common in children then adults. Pain swelling 
and wasting of thigh muscles are commonly seen. The knee feels warm. Movements 
are restricted and often painful. Mantoux test is positive and the erythrocyte 
sedimentation rate may be incresed. X-ray shows generalised decalfication, 
obiliterationof join space with erosion of the articular ends. 
Gonococcal 
 It occurs 3 weeks after the primary infection. Onset is sudden with fever. It 
mostly affects knee (or) elbow. Pain redness, head and oedema occur in the affected 
jion. Gonococcal may be demonstrated in urethral discharge. 
DISH: Diffuse Idiopathic Skeletal Hyperostosis 
 This is a comparatively common disorder of middle aged people, 
characterized by bone propagation at the ligament and tendon insertions around 
peripheral joints and the intervertebral discs. On X-ray examination the large bony 
spurs are easily mistaken for osteophytes. 
 DISH & osteoarthritis often appear together but DISH is not osteoarthritis, the 
bone spurs are symmetrically distributed particularly along the pelvic apophyses and 
all through the vertebral column. When DISH occurs by itself it is usually 
asymptomatic. 
Investigations 
 Blood counts, Erythrocyte sedimentation rate, blood chemistry and febrile 
agglutination tests are negative. 
 Thyroid profile reveals a hypothyroid state in 10% to 30% of patients 
 Synovial fluid examination serves to differentiate degenerative joint disease from 
rheumatoid arthritis and infectious arthritis. 
Radiological findings 
Early X-ray appearance is normal. Then gradually, 
 Narrowing of the joint space 
 Thinning of the articular cartilage 
 Spurs or osteophyte formation 
 Subchondral bone cyst formation 
 Sclerosis of the subchondral bone. 
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Radiological Classification of Osteoarthritis knee (Ahlbach) AP weight bearing 
and lateral View s. 
Diagnostic criteria 
Formal criteria are helpful for diagnosing osteoarthritis in knee joints. The criteria 
for osteoarthritis of the knee include the presence of knee pain plus atleast three of 
the following characteristics. 
Advice: 
 Each, and egery patient is adviced to do regular yoga excerises which 
strengthen! quadriceps muse lews and half muscles Avoid movements (or) positions, 
which increase patella femoral pressure. Avoid sitting crossed legged, climbing stairs 
and squatting position. 
 Use of walking sick hold in ipsilateral hand (or) use of crutches to preview 
stress on affected knee immobilize the knee by knee corest or a brace or classic 
bandape, if die pain is servere. weight reduction by exercise and diet control in 
advised. 
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MATERIALS AND METHODS 
 The clinical study on Azhal keel vayu (Osteoarthritis of knee joint) was 
carried out in the post graduate department of sirappu Maruthuvam, Government 
Siddha Medical College at Palayamkottai. In this Study 40 patients (who satisfy the 
inclusion criteria and exclusion criteria) were treated as op and IP. 
Selection of the patients: 
 Age :  30-60 years 
 Sex : Both male and female. 
 
Clinical finding 
Inclusion Criteria 
 The patients were selected on the basis of the following clinical findings. 
 Patients having symptoms of joint pain of both knee joints, swelling, 
tenderness, stiffness, crepitation, restricted movement of both knee joints. 
 Patient who are willing to give blood samples for laboratory investigation. 
 Patients who are willing to take X-ray before and after treatment. 
 Patients who are willing to participate in this study with the knowledge of 
potential risks. 
 
The detailed history was taken from the patient about 
1. Occupation 
2. Socio Economic Status. 
3. Diet and habits. 
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PAIN ASSESSMENT 
UNIVERSAL PAIN ASSESSMENT SCALE 
 
 
A -0  - No pain 
B-1-3  - Mild pain 
C-4-6  -           Moderate pain 
D-7-10              - Severe pain 
Reference: Clinical manual for Nursing practice (National Institute of Health warren 
grant mangneson clinical centre) 
 
GRADATION OF MOVEMENTS: 
 G1 - Fit for all activities, do their work without support. 
 G11 - Mild pain present in knee joint, mild restricted movement 
 G111 - Moderate pain present in knee joint, moderate restricted  
                      movements, need some assistance to perform 
 G1v - Severe pain, bed ridden 
 
Diagnosis: 
 The diagnosis was made by following siddha diagnostic methods  kalam, 
poriaridhal, pulanaridhal, udalthathukkal, naadi and envagai Thervu and the diagnosis 
of Azhal keel vayu obtained which correlated with modern diagnosis of osteoarthrity 
of knee joints by the X-Ray findings. 
 
Exclusion criteria: 
 Cardiac disease 
 Rheumatoid arthritis 
 Use of narcotic drugs 
 Pregnant woman and lactating mother 
 Patient with any other serious illness 
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 History of trauma 
 Benign and malignant neoplasm 
 Immuno compromised patients 
 Children, elderly 
 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of adverse reactions during drug trial. 
 Poor patient compliance & defaulters. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness 
 
INVESTIGATION: 
 The following investigations were done in all selected patients in the 
laboratory of Government Siddha Medical College, Palayamkottai. 
 
BLOOD: 
 Total WBC count 
 Differential WBC count 
 Erythrocyte sedimentation rate. 
 Haemoglobin estimation 
 Estimation of Blood sugar 
 Estimation of Blood urea 
 Estimation of serum cholesterol. 
 
URINE: 
 Albumin 
 Sugar 
 Deposit 
 
RADIOLOGIVAL INVESTICATIONS: 
 X-ray of both knee joint - ap view and lateral view 
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TREATMENT 
 Vellai ennai 15ml at early morning, in empty stomach with hot water. All the 
patients were treated with the following medicine. 
 Kalinga Mathirai (Internal) 65mg (BD) 
 Kodiveli thylam (External) 60ml, as external application 
 Pattru as external theraphy. 
All the patients were advised to follow the dietary regiment (or) pathiyam. 
 The Bio-chemical analysis was done in Biochemistry Department of 
Government Siddha Medical College and Pharmacological analysis was done in the 
pharmacological laboratory of kalasalingam university. 
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 OBSERVATION AND RESULT 
 For the clinical study 40 patients were selected and treated in PG-III Sirappu 
Maruthuvam Department, Government Siddha Medical College and Hospital, 
Palayamkottai. Results were observed with respect to the following criteria. 
1. Gender distribution 
2. Age distribution 
3. Kaalam 
4. Occupation 
5. Seasonal Variations 
6. Thinai 
7. Socio-economic status 
8. Directory habits 
9. Precipitating factors 
10. Mode of onset 
11. Duration of conditions 
12. Clinical features 
13. Conflict in Kanmathiriam 
14. Disturbance in Vatham 
15. Disturbance in Pitham 
16. Disturbance in Kabam 
17. Disturbance in Udal Kattugal 
18. Envagai thervugal 
19. Naadi 
20. Neikuri 
21. Assessment of results by the effect of conbined therapy. 
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OBSERVATION AND RESULTS 
1. GENERAL DISTRIBUTION 
    Table: 5.1 
 Gender No. of Cases Percentage (%) 
1 Male 15 37.5 
2 Female 25 62.5 
 Total 40 100 
 
    Fig: 5.1     
 
 
Inference: 
 Among 40 patients selected for this study. 62.5% are female and 37.5% are 
male. 
  
GENERAL DISTRIBUTION (%)
Male
Female
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2. AGE DISTRIBUTION 
    Table:5.2 
S.No. Age Year No. of Cases Percentage (%) 
1 30-40 7 17.5 
2 41-50 12 30 
3 51-60 21 52.5 
 Total 40 100 
 
    Fig:5.2 
 
 
Inference: 
 The prevalence of the diseases is found to be higher in the age group of 51-60 
years. 
  
AGE DISTRIBUTION (%)
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41-50
51-60
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3. KAALAM 
    Table:5.3 
S.No. Kaalam 
No. of 
Cases 
Percentage 
(%) 
1 Vathakaalam (upto 33yrs) 1 2.5 
2 
Pithakaalam upto 
(33 years & 66 years) 
39 97.5 
3 Kabhakaalam (Above 66 years) 0 0 
 TOTAL 40 100 
 
    Fig:5.3 
 
 
 
Inference: 
 Out of 40 cases, 97.5% of cases were founded to be in pitha kaalam. 2.5% of 
cases were found to be in Vadha kaalam. 
  
KAALAM(%)
Vathakaalam (upto 33yrs)
Pithakabalam upto
(33 years & 66 years)
Kabhakaalam (Above 66 
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4. OCCUPATION 
    Table:5.4 
S.No. Occupation 
No. of 
Cases 
Percentage 
(%) 
1 Farmer and Labour 17 42.5 
2 Carpenter / Mason 0 0 
3 Teacher 7 17.5 
4 Housewife 14 35 
5 House keeper 0  
6 Tailor 2 5 
 Total 40 100 
 
    Fig: 5.4 
 
Inference: 
 Out of 40 cases, in this study the rate of incidence is higher in occupational 
group which includes Farmers and Labour 42.5%, House wife 35% Teachers 17.5% 
and Tailor 5%. 
OCCUPATION (%)
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5. SEASONAL VARIATIONS 
    Table 5.5 
S.No. Seasons 
No. of 
Cases 
Percentage 
(%) 
1 Kaarkaalam ( Age 16 - Oct 15) 4 10 
2 Koothir kaalam (oct 16 - dec 15) 1 2.5 
3 Munpanikaalam (dec 16 - Feb 15) 9 22.5 
4 Pinpani kaalam (feb 16 - Apr 15) 12 30 
5 Ilavenir kaalam (Apr 16 - Jun 15) 3 7.5 
6 Muthuvenikaalam (Jun 16 - Aug 15) 11 27.5 
 Total 40 100 
 
    Fig:5.5 
 
Inference: 
 Out of 40 cases, 30 patients were admitted in Pinpani kaalam, 27.5% of 
patients were admitted in Muthuveni kaalam, 22.5% of patients were admitted in 
Munpanikalam, 10% of patients were admitted in Kaarkaalam, 7.5% of patients were 
admitted in Ilavenirkalam, 2.5% of patients were admitted in Koothirkalam. 
SEASONAL VARIATIONS(%)
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 6. THINAI 
    Table: 5.6 
S.No. Seasons 
No. of 
Cases 
Percentage 
(%) 
1 Kurinji (Hill area) 3 7.5 
2 Mullai (Forest area) 14 35 
3 Marutham (Fertile area) 17 42.5 
4 Neithal (Coastal area) 6 15 
5 Paalai (Desert land) 0 0 
 TOTAL 40 100 
 
    Fig: 5.6 
 
 
 
Inference: 
 Among 40 cases, majority were from Marutha Nilam (42.5%) 
 
THINAI (%)
Kurinji (Hill area)
Mullai (Forest area)
Marutham (Fertile area)
Neithal (Coastal area)
Paalai (Desert land)
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7. SOCIO ECONOMIC STATUS 
    Table 5.7 
S.No. Class 
No. of 
Cases 
Percentage 
(%) 
1 Rich 4 10 
2 Middle class 17 42.5 
3 Poor 19 47.5 
 Total 40 100    
 
                                                          Fig:5.7 
 
                                                             
 
 
Inference: 
 Out of 40 cases, 47.5% cases were from poor socio-economic status, 42.5% of 
cases from middle class and only 10% of cases from Rich background. 
 
  
SOCIO ECONOMIC STATUS(%)
Rich
Middle class
Poor
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8. DIETARY HABITS 
Table:5.8 
S.No. Dietary 
No. of 
Cases 
Percentage 
(%) 
1 Vegetarian 14 35 
2 Non-vegetarian 26 65 
 TOTAL 40 100 
 
Fig :5.8 
 
 
 
 
 
 
 
Inference: 
 Most of the cases have non-vegetarian diet habit (65%) 
  
DIETARY HABITS (%)
Vegetarian
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9. PRECIPITATING FACTORS 
Table 5.9 
S.No. Precipitating Factors 
No. of 
Cases 
Percentage 
(%) 
1 Trauma 0 0 
2 Obesity 15 37.5 
3 Occupation related over of the joint 12 30 
4 Menopause 11 27.5 
5 Hereditary 2 5 
 Total 40 100 
 
Fig 5.9 
 
 
Inference: 
 Among the 40 cases, 15 patients of them (37.5%) were obese, 12 patients of 
them (30%) had history of over use of the joint, 11 patients of them (27.5%) were in 
post menopausce stage, 2 patients of them (5%) were hereditary. 
 
PRECIPTATING FACTORS (%)
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Menopause
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10. MODE OF ONSET: 
Table 5.10 
S.No. Mode of Onset 
No. of 
Cases 
Percentage 
(%) 
1 Acute 10 25 
2 Gradual 30 75 
 Total 40 100 
 
 
                                                              Fig 5.11 
 
 
Inference: 
 According to this study 75% of the cases were reported gradual onset of 
disease. 
 
  
MODE OF ONSET (%)
Acute
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11. DURATION OF CONDITIONS: 
Table 5.11 
S.No. Duration (Months) 
No. of 
Cases 
Percentage 
(%) 
1 0-3 26 65 
2 4-6 7 17.5 
3 7-12 5 12.5 
4 13-24 2 5 
5 Above 24 0 0 
 TOTAL 40 100 
 
Fig 5.11 
 
 
Inference: 
 Among the 40 cases, 26 cases (65%) were come under 0-3 months, 7 cases 
(17.5%) were come under 4-6 months, 5 cases (12.5%) were come under 7-12 
months, 2 cases (5%) were come under 13-24 months. 
 
DURATION OF CONDITION(%)
0.3
4.6
7.12
13.24
Above 24
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12. CLINICAL FEATURES: 
    Table:5.12 
S.No. Duration (Months) 
No. of 
Cases 
Percentage 
(%) 
1 Pain 40 100 
2 Swelling 22 55 
3 Tenderness 10 25 
4 Morning stiffness 10 25 
5 Crepitation 18 45 
6 Deformity 1 2.5 
7 Restricted movement 11 27.5 
  
Fig:5.12 
 
 
Inference: 
 Pain were found in all 40 cases (100%) 
 Swelling found in 22 cases (55%) 
 Crepitation were found in 18 cases (45%) 
 Restricted movement present in 11 cases (27.5%) 
 Tenderness were found in 10 cases (25%) 
 Morning stiffness was found in 10 cases (25%) 
 Deformity present in 1 case (2.5%) 
 
 
 
 
CLINICAL FEATURES (%)
Pain
Swelling
Tenderness
Morning stiffness
Crepitation
Deformity
Restricted movement
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13. CONFLICT IN KANMENTHIRIAM: 
 
Table 5.12 
S.No. Kanmenthiriam 
No. of 
Cases 
Percentage 
(%) 
1 Vaai 0 0 
2 Kai 0 0 
3 Kaal 40 100 
4 Eruvai 12 30 
5 Karuvai 0 0 
 TOTAL 40 100 
 
 
Fig:5.12 
 
 
 
 
 
 
Inference: 
 Among all the Kanmenthiriam (Vaai, Kai, Kaal, Kruvai, Karuvai) Kaal was 
affected in all 40 cases (100%) and Eruvai was affected in 12 cases (30%) 
  
CONFLICT IN KANMENTHIRIAM (%)
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14: TABLE SHOWING THE DISTURBANCES IN VATHAM: 
S.No. Vatham 
No. of 
Cases 
Percentage 
(%) 
1 Pranan 0 0 
2 Abanan 12 30 
3 Udhanan 0 0 
4 Viyanan 40 100 
5 Samanan 40 100 
6 Nagan 0 0 
7 Koorman 0 0 
8 Kirukaran 9 22.5 
9 Devathathan 9 22.5 
10 Dhananjeyan 0 0 
 
Fig:5.14 
 
Inferences: 
 Viyanan and Samanan were affected in all the 40 cases (100%) Abanan were 
affected in 12 cases (0%) Kirukaran and Devathathan affected in 9 cases (22.5%) 
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15.DISTURBANCES IN PITHAM 
Table:5.15 
S.No. Duration (Months) 
No. of 
Cases 
Percentage 
(%) 
1 Anar Pitham 9 22.5 
2 Ranjaga Pitham 10 25 
3 Sathaga Pitham 40 100 
4 Prasaga Pitham 0 0 
5 Alosaga Pitham 0 0 
 
Fig:5.16 
 
 
 
Inference: 
 Sathga Pitham was affected in all the 40 cases (100%) Ranjaga pitham was 
affected in 10 cases (25%), Anarpitham was affected in 9 cases (22.5%) 
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16 DISTURBANCE OF KABAM: 
Table:5.16 
S.No. Duration (Months) 
No. of 
Cases 
Percentage 
(%) 
1 Avalambagam 40 100 
2 Kilathagam 0 0 
3 Bothagam 0 0 
4 Tharpagam 0 0 
5 Santhigam 40 100 
 
Fig:5.16 
 
 
 
Inference: 
 Among all Santhigam and Avalambagam was affected in all 40 cases (100%) 
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17.DISTURBANCE IN UDAL KATTUGAL: 
Table 5.17 
S.No. Udal Kattugal 
No. of 
cases 
Percentage 
(%) 
1 Saaram 40 100 
2 Seneer 10 25 
3 Oon 0 0 
4 Kozhuppu 40 100 
5 Enbu 40 100 
6 Moolai 0 0 
7 Sukilam / Surondidham 0 0 
 
Fig: 5.17 
 
 
Inference: 
 It was diagnosed, during the study that among the seven udalkattukal, Saaram, 
Kozhuppu, Enbu were affected in 40 cases (100%) and Seneer is affected in 10 cases 
(25%) 
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18.DISTURBANCE IN ENVAGAI THERVUGAL: 
Table 5.18 
S.No. Envagai Thervugal 
No. of 
Cases 
Percentage 
(%) 
1 Naa 0 0 
2 Niram 0 0 
3 Mozhi 0 0 
4 Vizhi 0 0 
5 Malam 12 30 
6 Moothiram 0 0 
7 Sparisum 0 0 
8 Naadi 40 100 
 
Fig 5.18 
 
Inference: 
 It was learnt during the study that Naadi was noted in all 40 cases (100%) 
Malam was affected in 12 cases (30%) 
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19.PULSE READING (NAADI) 
Table 5.19 
S.No. Parameters 
No. of 
Cases 
Percentage 
(%) 
1 Vathapitham 24 60 
2 Pithavatham 12 30 
3 Kabavatham 4 10 
 
Fig 5.19 
 
 
 
Inference: 
 As mentioned above naadi was noted in all cases and among that 24 cases 
(60%) were vathapitham, 12 cases (30%) were pithavatham, and remaining 3 cases 
(4%) were kabavatha naadi. 
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20 NEIKURI 
Table 5.20 
S.No. Inference 
No. of 
Cases 
Percentage 
(%) 
1 Spreading like snake (vatha neer) 20 50 
2 Spreading like aring (pitha neer) 10 25 
3 Stands like a pearl (kaba neer) 10 25 
4 Combination of ring and snake 0 0 
 
Fig 5.20 
 
 
 
 
Inference: 
 In Neikuri analysis, 50% of the cases presented with Vatha neer, 25% with 
pithaneer 25% with kaba neer. 
NEIKURI (%)
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21:ASSESSMENT OF RESULT BY THE EFFECT OF COMBINED 
THERAPY 
Table 5.21 
S.No. Effect of therapy No of patients Percentage (%) 
1 Marked effect 17 42.5 
2 Moderate effect 17 42.5 
3 Mild effect 6 15 
4 No effect 0 0 
 
Fig 5.21 
 
 
Inference: 
 Thus from the analysis of the data collected during the course of treatment and 
at the end of treatment it is inferred that the overall effect of the therapy. Internal, 
external and complementary. Marked effect of 42.5% moderate effect of 17.5% and 
mild effect of 15% 
ASSESSMENT OF RESULT BY THE 
EFFECT OF COMBINED THERAPY.
(%)
Marked effect
Moderate effect
Mild effect
No effect
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Measurement of the Knee Joint 
S. 
No. 
Patient Name Age / Sex OP / Ip No. 
Before Treatment After Treatment 
Right (cm) Left (cm) Right (cm) Left (cm) 
1 Seetha 41/F 21791 32 35 30 33 
2 Alipathima 40/F 36234 38 40 35 36 
3 Sudalai Vadivu 57/F 1815 33 37 30 33 
4 Perumail 60/F 107 37 36 33 30 
5 Sivagami 55/F 25557 41 39 39 37 
6 Chandira 35/F 3127 34 33 32 32 
7 Murugan 52/M 23662 39 38 35 35 
8 Maryammal 59/F 17226 31 33 26 28 
9 Vijaya 43/F 2261 33 32 29 30 
10 Malaiyandi 55/M 2892 39 36 35 34 
11 Annamiyail 40/F 111 30 32 28 30 
12 Chellammal 60/F 394 36 35 32 31 
13 Nagarajan 60/M 417 41 39 38 37 
14 Gomathi 56/F 2195 83 30 31.5 28 
15 Lakshmi 33/F 21961 33 32 29 30 
16 Maryammal 60/F 2320 40 39 35 34 
17 Pathrakali 60/F 1778 37 36 33 32 
18 Narayanasamy 57/M 1592 40 38 38 35.5 
19 Aarumugam 50/F 293 32 37 30 34 
20 Sankaran 60/M 2091 35 33 31 30 
21 Velammal 55/F 2190 41 39 38 37 
22 Perumail 60/M 415 35 32 32 30 
 
INFERENCE: Knee joint Swelling is reduced approximately 2-3cms after treatment. 
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CASE PRESENTATION - SUMMARY OF OUR PATIENTS 
1. KALINGA MATHIRAI - INTERAL   2. KODIVELI THYLAM- EXTERNAL 
S. 
NO. 
OP. 
NO. 
NAME AGE / SET OCCUPATION 
DATE  OF 
REGISTRATION 
DATE OF  
COMPLETION  
OF  
TREATMENT 
NO. 
OF 
DAYS 
TREATED 
RESULT 
1 2261 Vijaya 43/F TEACHER 4.6.2018 07.07.2018 34 MODERATE 
2 50047 Rubi 48/F TAILOR 12.06.2018 29.07.2018 45 MARKED 
3 36234 Alipathima 40/F TEACHER 02.07.2018 15.08.2018 45 MODERATE 
4 25626 Muthulingam 57/M FARMER 07.07.2018 08.08.2018 33 MARKED 
5 2892 Malaiyandi 55/M FARMER 25.07.2018 18.08.2018 25 MILD 
6 23679 Murugan 45/M FARMER 04.02.2019 22.03.2019 47 MARKED 
7 23779 Valli 40/F HOUSE WIFE 06.02.2019 20.03.2019 43 MODERATE 
8 23648 Chellammal 50/F HOUSE WIFE 07.02.2019 16.03.2019 48 MODERATE 
9 16924 Baliya 50/M FARMER 15.02.2019 22.03.2018 36 MARKED 
10 17059 Meenachi 38/F HOUSE WIFE 15.02.2019 29.03.2019 43 MODERATE 
11 17226 Mariyammal 59/F HOUSE WIFE 15.02.2019 28.03.2019 42 MODERATE 
12 21791 Seetha 41/F HOUSE WIFE 01.03.2019 13.04.2019 44 MODERATE 
13 21961 Lakshmi 33/F TAILOR 01.03.2019 18.04.2019 49 MILD 
14 21980 Sivarajan 46/M FARMER 01.03.2019 14.04.2019 45 MARKED 
15 23661 Selvi 46/F HOUSE WIFE 07.03.2019 22.04.2019 47 MILD 
16 23662 Murugan 52/M FARMER 07.03.2019 16.04.2019 41 MODERATE 
17 23663 Aarumugam 51/M FARMER 07.03.2019 12.04.2019 37 MARKED 
18 23370 Saaji muthu 60/M TEACHER 13.03.2019 22.04.2019 40 MODERATE 
19 25557 Sivagami 55/F HOUSE WIFE 13.03.2019 20.04.2019 38 MARKED 
20 26678 Muthuvelii 43/F TEACHER 16.03.2019 23.04.2019 38 MARKED 
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LIST OF IN PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT 
1. KALINGA MATHIRAI - INTERNAL     2. KODIVELI THYLAM - EXTERNAL 
S.NO. IP.NO. NAME AGE / SET OCCUPATION 
DATE OF 
ADMISSION 
DATE OF 
DISCHARGE 
NO. 
OF 
DAYS 
TREATED 
TOTAL NO 
OF DAYS 
RESULT 
IP OP 
1 1898 M.RANI 60/F FARMER 04.06.2018 29.06.2018 26 20 46 MILD 
2 1598 NARAYANA SAMY 57/F FARMER 20.06.2018 31.08.2018 51 0 51 MODERATE 
3 1778 PATHIRA KALI 60/F HOUSE WIFE 12.07.2018 16.08.2018 37 11 48 MARKED 
4 1815 SUDALAI VADIVOO 57/F FARMER 17.07.2018 27.08.2018 42 6 48 MODERATE 
5 2020 SELVI 38/F HOUSE WIFE 06.08.2018 11.09.2018 37 11 48 MARKED 
6 2032 AARUMUGASAMY 47/F FARMER 07.08.2018 03.09.2018 29 19 48 MILD 
7 2091 SANKARAN 60/M FARMER 16.08.2018 03.09.2018 19 31 50 MILD 
8 2190 VELAMMAL 55/F HOUSE WIFE 27.08.2018 27.09.2018 32 16 48 MARKED 
9 2195 GOMATHI 56/F TEACHER 27.08.2018 27.09.2018 32 16 48 MARKED 
10 2320 MARIYAMMAL 60/F HOUSE WIFE 11.09.2018 16.10.2018 36 13 49 MODERATE 
11 3036 DEVAPAIL 60/M FARMER 11.12.2018 01.01.2019 22 26 48 MARKED 
12 3127 CHANDIRA 35/F HOUSE WIFE 22.12.2018 15.01.2019 25 23 48 MARKED 
13 107 PERUMAIL 60/F FARMER 21.01.2019 13.02.2019 24 24 48 MARKED 
14 111 ANAMERIYAL 40/F HOUSE WIFE 21.01.2019 23.02.2019 34 15 49 MODERATE 
15 293 AARUMUGAM 50/F FARMER 08.02.2019 07.03.2019 28 20 48 MODERATE 
16 394 CHELLAMAL 60/F HOUSE WIFE 18.02.2019 25.03.2019 36 15 50 MODERATE 
17 415 PERUMAIL 60/M FARMER 19.02.2019 19.03.2019 29 19 48 MARKED 
18 417 NAGARAJAN 60/M FARMER 19.02.2019 19.03.2019 29 19 48 MARKED 
19 435 KERUSTI 60/F HOUSE WIFE 20.02.2019 27.03.2019 36 13 48 MODERATE 
20 464 AARUMUGAM 48/F TEACHER 23.02.2019 29.03.2019 35 14 48 MODERATE 
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BLOOD INVESTIGATION BEFORE AND AFTER TREATEMENT - OP PATIENT 
    TC DC HB ESR 
BLOOD  
SUGAR 
      UREA SERUM CHOLOTER 
S.NO. OP.NO. BT AT ST AT BT AT BT AT BT AT BT AT BT AT BT AT F   PP           
        N   L   E   B   M           BT AT BT AT BT AT BT AT 
1 2261 6300 6900 66 60 33 34 1 1 0 0 0 0 101 12 22 12 76 78 120 110 34 30 150 146 
2 50047 7000 7100 59 55 37 36 4 4 0 0 0 0 9 10.2 25 15 80 82 130 126 24 26 185 170 
3 36837 6800 7000 68 45 29 30 3 3 0 0 0 0 12 11.3 34 20 86 88 126 130 26 24 250 230 
4 25626 6200 6500 59 50 36 37 5 4 0 0 0 0 13 13.1 18 10 98 49 128 120 30 26 205 200 
5 2892 7800 8000 63 60 35 33 2 3 0 0 0 0 11.9 12 15 8 88 85 120 160 32 30 170 160 
6 23679 8200 7500 71 60 24 30 5 4 0 0 0 0 12.2 12.1 26 16 86 90 123 138 36 32 159 160 
7 23779 6900 6700 61 53 34 29 5 3 0 0 0 0 10.5 11.5 28 20 79 77 132 120 38 36 199 200 
8 23648 7300 7100 59 55 36 32 5 3 0 0 0 0 12.4 11.2 11 8 90 88 110 100 36 35 194 180 
9 16924 8200 8000 68 68 29 25 3 4 0 0 0 0 13.6 13 15 10 88 85 115 120 29 32 139 150 
10 17059 6700 6900 60 61 26 24 14 6 0 0 0 0 10.1 11.5 31 22 80 75 100 110 28 29 179 180 
11 17226 7700 7700 60 52 33 30 7 4 0 0 0 0 12.5 12.5 18 14 50 70 90 100 40 35 240 220 
12 21791 7500 8100 60 51 30 28 10 6 0 0 0 0 9.5 11 19 10 79 77 90 95 23 25 232 220 
13 21961 8800 8900 59 54 37 35 4 4 0 0 0 0 12.2 13.5 26 12 87 83 107 110 28 27 159 130 
14 21980 7300 7500 63 60 24 22 13 4 0 0 0 0 11.9 12 36 20 80 82 100 105 36 32 208 210 
15 23661 9200 9100 59 45 36 34 5 3 0 0 0 0 10 11.3 28 14 87 90 97 110 29 33 159 140 
16 23662 6700 6900 64 43 33 25 3 2 0 0 0 0 11.1 11.2 16 8 83 87 100 110 19 27 221 210 
17 23643 7300 7100 60 57 35 29 5 1 0 0 0 0 18.2 12.5 10 10 82 90 110 120 20 23 185 180 
18 23376 8000 8200 59 51 36 30 5 1 0 0 0 0 13 13 32 16 83 87 100 110 21 22 179 160 
19 25557 6700 6900 65 60 25 23 10 4 0 0 0 0 9.6 10.5 34 20 99 98 105 100 26 27 160 150 
20 26678 9200 900 60 58 33 35 7 5 0 0 0 0 12.2 12.5 16 14 87 90 110 100 30 29 200 196 
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BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT - IP PATIENT 
  
TC DC HB ESR BLOOD SUGAR UREA SERUM CHOLOTER 
S.NO. OP.NO. BT AT 
N 
 
L 
 
E 
 
B 
 
M 
 
BT AT BT AT F PP 
    
BT AT BT AT BT AT BT AT BT AT 
    
BT AT BT AT BT AT BT AT 
1 1898 6900 7000 64 60 29 30 7 4 0 0 0 0 41.5 12 12 10 82 80 120 10 28 23 240 222 
2 1598 6700 6500 70 58 25 26 5 4 0 0 0 0 10 11.2 29 12 76 15 100 105 36 33 170 173 
3 1778 6800 6900 55 52 35 30 10 3 0 0 0 0 13 13.1 30 15 88 89 110 105 40 35 183 180 
4 1815 7700 8200 64 60 30 31 6 2 0 0 0 0 9.6 10.5 16 15 90 84 130 125 23 22 150 133 
5 2020 7200 7500 60 60 24 26 16 5 0 0 0 0 12.1 12.3 18 16 80 87 120 124 36 35 194 173 
6 2032 8000 7900 64 59 32 30 4 3 0 0 0 0 12 11.5 20 18 60 69 115 116 29 32 176 173 
7 2091 8100 8500 65 55 25 26 10 2 0 0 0 0 10.9 11 14 13 67 70 97 100 19 22 159 160 
8 2190 9200 9500 71 60 24 20 5 1 0 0 0 0 11.2 12 9 10 65 90 96 106 21 23 208 194 
9 2195 7000 7300 65 58 30 26 5 1 0 0 0 0 8 10 10 12 89 90 120 116 26 24 201 210 
10 2320 9800 9900 70 60 20 21 10 4 0 0 0 0 11.5 12 12 10 87 89 118 120 30 25 179 160 
11 3036 6700 7000 60 60 30 32 10 4 0 0 0 0 12.8 12.5 15 14 99 74 140 135 32 31 160 140 
12 3127 19000 9800 50 49 40 36 10 3 0 0 0 0 13.2 13.7 17 15 87 89 130 120 26 25 240 233 
13 107 8000 8100 62 60 32 30 6 2 0 0 0 0 12.7 12.8 18 10 76 79 132 133 34 32 165 157 
14 111 9200 9400 60 62 37 35 3 1 0 0 0 0 7.5 9.8 16 12 79 80 124 116 24 24 160 165 
15 293 6200 6400 65 59 30 40 5 4 0 0 0 0 12.2 13 19 16 85 86 125 122 32 31 203 200 
16 394 6500 6300 64 59 29 30 7 3 0 0 0 0 12.1 12 15 14 70 78 110 103 38 30 146 143 
17 415 6700 6900 60 60 29 25 11 5 0 0 0 0 13.2 13.5 9 10 82 86 133 124 40 32 160 154 
18 417 8200 8300 62 60 28 29 10 2 0 0 0 0 10.2 
 
10 12 87 89 126 128 29 25 200 205 
19 435 7700 7800 70 60 25 27 5 5 0 0 0 0 11 11.5 13 16 73 78 105 110 24 23 221 210 
20 464 6800 6900 60 59 34 40 16 5 0 0 0 0 9 11 16 14 76 79 116 120 29 26 180 174 
 
 
97 
 
URINE EXAMINATION BEFORE & AFTER TREATMENT - OUT PATIENTS 
S.NO. OP.NO. 
BEFORE TREATMENT AFTER TREATMENT 
ALBUMIN SUGAR DEPOSIT ALBUMIN SUGAR DEPOSIT 
1 2261 NIL NIL NIL NIL NIL NIL 
2 50047 NIL NIL NIL NIL NIL NIL 
3 36234 NIL NIL NIL NIL NIL NIL 
4 25626 NIL NIL NIL NIL NIL NIL 
5 2892 NIL NIL NIL NIL NIL NIL 
6 23679 NIL NIL NIL NIL NIL NIL 
7 23779 NIL NIL NIL NIL NIL NIL 
8 23648 NIL NIL NIL NIL NIL NIL 
9 16924 NIL NIL 1-2 BUS CELLS NIL NIL NIL 
10 17059 NIL NIL NIL NIL NIL NIL 
11 17226 TRACE NIL NIL NIL NIL NIL 
12 21791 NIL NIL NIL NIL NIL NIL 
13 21961 NIL NIL NIL NIL NIL NIL 
14 21980 NIL NIL NIL NIL NIL NIL 
15 23661 NIL NIL NIL NIL NIL NIL 
16 23662 NIL NIL NIL NIL NIL NIL 
17 23663 NIL NIL 3-6 PUS CELLS NIL NIL NIL 
18 23370 NIL NIL NIL NIL NIL NIL 
19 25557 NIL NIL NIL NIL NIL NIL 
20 26678 NIL NIL 1-2 PUS CELLS NIL NIL NIL 
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URINE EXAMINATION BEFORE & AFTER TREATMENT - IN PATIENTS 
  
S.NO. 
  
IP.NO. 
BEFORE TREATMENT AFTER TREATMENT 
ALBUMIN SUGAR DEPOSIT ALBUMIN SUGAR DEPOSIT 
1 1898 NIL NIL 4-6 PUSCELLS NIL NIL 1-2 DEPOSITS 
2 1598 NIL NIL NIL NIL NIL NIL 
3 1778 NIL NIL NIL NIL NIL NIL 
4 1875 NIL NIL NIL NIL NIL NIL 
5 2020 NIL NIL NIL NIL NIL NIL 
6 2032 NIL NIL NIL NIL NIL NIL 
7 2091 NIL NIL NIL NIL NIL 1-2 PUS CELLS 
8 2190 NIL NIL 3-6 PUS CELLS NIL NIL NIL 
9 2195 NIL NIL NIL NIL NIL NIL 
10 2320 TRACE NIL TRACE NIL TRACE NIL NIL 
11 3036 NIL NIL NIL NIL NIL NIL 
12 3127 NIL NIL NIL NIL NIL NIL 
13 107 NIL NIL NIL NIL NIL NIL 
14 111 NIL NIL NIL NIL NIL NIL 
15 293 NIL NIL NIL NIL NIL NIL 
16 394 NIL NIL NIL NIL NIL NIL 
17 415 NIL NIL NIL NIL NIL NIL 
18 417 NIL NIL NIL NIL NIL NIL 
19 435 TRACE NIL NIL TRACE NIL NIL 
20 464 NIL NIL NIL NIL NIL NIL 
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DISCUSSION 
 Osteoarthritis is a chronic disorder of synovial joints in which there is 
progressive softening and disintegration of articular Cartilege and bone at the joint 
margins (Osteophytes) cyst formation and subchondral sclerosis, mild synovitis and 
capsular fibrosis. 
 
Classified as: 
o Primary (Localized or generalized) 
o Secondary (Traumatic, congenital, Metabolic) 
o Characterized by focal and progressive loss of hyaline cartilage of 
joint. 
Symptoms: 
 Pain 
 Swelling 
 Cripitus 
 Stiffness 
The trial drug given below was used in treating the disease azhal keel vaye the 
trial drug are. 
 KALINGA MATIRAI - INTERNAL 
 KODIVELI THYLAM  - EXTERNAL  
 The clinical approval was done as per the protocol and the data were collected 
by using approved forms. The disease Azhal Keel Vayu (Osteoarthritis of knee joint) 
was considered under various criteria to gather the secondary objectives of the study 
and the result were observed and tabulated. A variety of criteria and the result were 
discussed here under. 
 
Gender Distribution: 
 From the above tabulation. Among the 40 patients selected,62.5% were 
female, and 37.5% were female. 
 
Age distribution: 
 Among the 40 patients selected this study shows high incidence of Azhal Keel 
Vayu (asteoarthritis of knee joint) was in above 51-60years (52.5%) of age, Azhal 
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Keel Vayu which is compared with osteoarthritis of knee joint which is degenerative 
disease, so the above interference  explained it’s significant as the age plays an 
important role upon the degenerative disease. 
 
Kaalam Distribution: 
 From the above mentioned tabulation, Among the 40 patients selected in this 
study, its shows the higher incidence was initiated to be pitha kaalam (97.5%). 
 
Occupational Status: 
 In this study, the rate of incidence is higher in occupational group which 
includes farmers and labours (42.5%) House wifes (35%) Teachers (17.5%) and 
Tailors (5%). This study shows heavy work farmets and Labours are mostly affected. 
 
Seasonal variations: 
 From the above mentioned tabulation 27.5% of patients were admitted in 
Muthuvenil kaalam, 22.5% of patients were admitted in munpanikaalam, 10% of 
patients were admitted in karkalam, 7.5%  patients were admitted in ilavenir kaalam 
25% of patients were admitted in koothirkulam. Mostly  the patients were admitted in 
Muthuvenil kaalam. 
 
Thinai 
From the above mentioned tabulation 17 cases (42.5%) were from maratham, 
14 cases (35%) were from Mullai, 6 cases (15%) were from Neithal, 3 cases (7.5%) 
were from Kurinji. 
 Even though siddha literatures mention maratham as a disease free 
zone,most of the patients came from maratham nilam. This may be due to the altered 
lifestyle,environment and food habits. Since this is a single centered study, located in 
maratham thinai it may also have influenced the study. 
 
Socio-economic status: 
From the above mentioned tabulation, out of 40 patients, 47.5% were from 
poor socio-economic status. 42.5% of cases from rich background. The higher 
incidence in the low socio-economic status may be due to the over usage by farmer, 
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and manual worker among the poor. The incidence in the further population group 
may be due to improper nutrition and also the people living in poor sanitation. 
 
Dietary habits: 
From the above mentioned tabulation patients 65% were reported to have 
Non-vegetarian, 35% were reported vegetarian, so this has no statistically significant 
result. 
 
Precipitating faction: 
From the mentioned above tabulation result that the above obese 37.5%, the 
occupation related 30%, post menopause 27.5%. Hereditary 5% were the most 
important precipitating factors. 
 
Mode of onset: 
 From the above mentioned tabulation it shows that 75% of the cases were 
reported to have graduate onset. 
 Since Osteoarthritis is a degenerative disorder it usually has a gradual onset of 
symptoms. 
 
Clinical features: 
 According to this study 100% of them had pain, 55% of them had swelling, 
crepitedion (45%). Restricted movement (27.5%) Tenderness (25%) Morning 
Stiffness (25%) Deformity (2.5%). 
 
Distribution in Kanmenthiram: 
 From the above mentioned tabulation, among the patients Kaal have been 
affected in 100% of cases and in 12 patients eruvai have been affected (30%). 
 
Distribution of Three Dhosham: 
Derangement in Vatham: 
 Viyanan and Samanan were affected in all 40 cases (100%) Abanan were 
affected in 12 cases (30%) and Kirukaran and Devathathan affected 9 cases (22.5%). 
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Derangement of Pitham: 
  Sathaga pitham was affected in all 40 cases (100%) Ranjagapitham was 
affected in 10 cases (25%), Anarpitham was affected in 9 cases (22.5%). 
 
Derangement in Kabam: 
 Avalambagam, Santhigam was affected in all 40 cases 100%. 
 
Udal Kattukal: 
 In all 40 cases, among the seven udal kattukkal saaram, kozhuppu Enbu were 
found affected 100% (Restricted Movement, Swelling, Crepitations present) and 
seneer is affected in 10 cases (25%).   
 
Envagai Theruvugal: 
 The analysis showed the efficacy of this method and the Prime importance of 
Naadi. 
 Among the 40 cases Naadi have been affected in all cases while malam have 
affected in 12 cases (30%). 
 
Naadi: 
 In Naadi among all 60% were Vathapitha Naadi, 30% were Pithavatha Naadi 
and remaining 10% were having Kabavatha Naadi. 
 
Neikuri: 
 In Neikuri analysis, 50% of the cases presented with Vatha Neer, 25% with 
Pithaneer and 25% with Kabaneer. 
 Laboratory investigations were done in all the cases before and after treatment. 
The significant variations occur in parameters like Hb, while other parameters have 
insignificant variation. 
 
Pre-Clinical Studies: 
 The Biochemical study of KALINGA MATHRAI had revealed the presence 
of Calcium, Sulphate, Chloride, Starch, Ferrous Iron, unsaturated campound, 
Reducing sugar, Amino Acid. 
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Pharmacological Studies: 
 The Pharmacological Studies done in KALINGA MATHIRAI revealed at 
presence of action such as 
1. Anti inflammatory action 
2. Analgesic activity 
 
Toxicity Studies: 
 Acute toxicity and Subacute studies have done for KALINGA MATHIRAI in 
rats and it is analysed that they have no toxicity. 
 
Treatment: 
 The treatment was aimed to retain the deranged dhosham and providing relief 
from symptoms. Before treatment the patient were advised to take vellai ennai - 15ml 
with hot water during early morning in empty stomach for first day of treatment. The 
patients was asked to take rest from internal Medicine and other activities on that day. 
From the next day onward the internal medicine to be given. 
 The author treated the patients with trial drugs KALINGA MATHIRAI 
(Internal Medicine) 65mg BD and KODIVELI THYLAM (External Medicine) and 
PATTRU (External Therapy) During treatment, the patients were advised to follow 
pathiyam (avoid tarmarind, tubers, meat etc). But all aspects of pathiyam could not be 
imposed due to practical difficulties. 
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SUMMARY 
 The disease Azhal Keel Vayu was mostly correlated with the disease 
osteoarthritis with reference to its etiology, clinical features and pathogenesis. It is the 
most commonest form of arthritis among the peoples above 50 years. 
 I have taken this as my dissertation and treated with KALINGA MATHIRAI 
as internal medicine and KODIVELI THYLAM as external medicine in Azhal Keel 
Vayu (osteoarthritis of Knee joint) 
 40 cases with azhal keel vayu were diagnosed clinically and admitted in the 
inpatient ward and outpatient ward of post graduation department of Sirappu 
Maruthuvam, Government Siddha Medical College hospital, palayamkottai and 
treated by the trial medicines. 
 Laboratory diagnosis of azhal keel Vaayu was done by Siddha Diagnostic 
principles and endorsed by modern methods of investigation. 
 The various Siddha aspects of examination of the disease were carried out and 
were recorded in the proforma. 
 The trial medicine chosen for both internal and external treatment were 
KALINGA MATHIRAI in 65mg twice a day for fortyeight days as per the 
severity of the diseases KODIVELI THYLUM external. 
 Before starting the treatment careful details of history was carried out and 
recorded for the forty selected cases. 
 During the period of treatment all the patients were put under Pathiyam. [A 
specific dietary regimen.] 
 A periodical laboratory investigation was made for all the cases along with the 
radiological investigations. 
 The observations made during the clinical study show that the main internal 
drug KALINGA MATHIRAI in clinically effective. 
 Though there was appreciable clinical improvement, there were not much 
remarkable radiographic changes. 
 The action of combined treatment were given best results in patients. 
Treatment: 
 The treatment was aimed to retain the deranged dhoshas and providing relief 
from symptoms. Before treatment the patients were advised to take vellai 
ennai-15ml with hot water in early morning for first day of treatment. 
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 From the second day onwards internal medicine. KALINGA MATHIRAI 
65mg two times day after food and KODIVELI THYLUM and PATTRU is 
given as external theraphy. 
 At the time of treatment the patients were advised to follow pathiyam and 
specially advised to avoid foods which increase vadha. 
 Daily improvement was observed to assess the efficacy. The results obtained 
were found to be propitious particularly results by combined therapies. 
 No adverse reactions were found. Hence, the trial drug was found to be safe 
and effective. 
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CONCLUSION 
 All 40 patients (Both OPD and IPD with as combined therapies with trial 
medicines) were treated for this dissertation work with KALINGA MATHIRAI 65mg 
two times a day and KODNELI THYLAM and PATTRU (external) 
 In the pre clinical study pharmacological evaluation of the trial drug shows. 
 significant analgesic effect 
 significant Anti inflammatory effect (internal medicine) 
 In the preclinical study toxicity study of ‘KALINGA MATHIRAI’ shows that 
the trial drug had no acute toxicity. 
 The over all effect of the clinical trial drug are  
 Marked effect   - 42.5% 
 Moderate effect  - 42.5% 
 Mild effect         -15%    
 No effect           -0%   
  This result of the clinical trial illustrates the marked effect of the drug 
and complementary therapy. 
  The trial drug KALINGA MATHIRAI Internal and KODIVELI 
THYLAM AND PATTRU as outornal therapy is effective. No adverse effect were 
noticed during the treatment period. So the trial a medicine is safe and easily 
preparable medicine. 
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INGREDIENTS OF KALINGA MATHIRAI  (INTERNAL)          
 
AATTRU THUMATTIVER                                                  
 
 
 
 
\ 
THIPPILI 
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INGREDIENTS OF KODIVELI THYLAM (Internal) 
 
 
KODIVELIVER 
 
 
 
 
 
THALISA PATHERI 
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BUTTER 
 
 
GINGELY OIL 
 
 
KARUNCHEERAGAM 
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THANTRIKAI 
 
 
 
 
 
COW MILK 
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EXTERNAL THERAPY(PATTRU) 
 
KOLLAN KOVAI 
 
 
 
  
 
 
 
VEENGAYAM 
 
 
 
 
 
 
 
 
CHEERAGAM 
 
 
 
AMANAKKU ENNAI
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KALINGA MATHERAI (INTERNAL) 
 
 
KODIVELI THYLAM (EXTERNAL) 
 
 
PATTRU (EXTERNAL THERAPY) 
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PATTRU (EXTERNAL THERAPY) 
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ANNEXURE-1 
PREPARATION AND PROPERTIES OF THE TRIAL DRUG 
INTERNAL MEDICINE: KALINGA MATHIRAI 
(Ref:GUNAPADAM MOOLIGAI Page no91) 
 
PURIFICATION: 
All above  drugs are purified under the formulation of “Anupoga Vaithiya Bramma 
Ragasiyam and Sarakku Suthi Muraigal” 
 Dose   : 65 Mg 
 Duration : 30 - 48 days 
 
SOURCE OF TRIAL MEDICINE: 
            The required drugs for preparation of “KALINGA MATHIRAI” 
(INTERNAL), “KODIVELI THYLAM” (EXTERNAL) are purchased from a well 
reputed country shopand Raw drugs are Authenticated by Medical botanist of Govt. 
Siddha Medical College, Palayamkottai, then  purified and the  medicine  is prepared 
in the  Gunapadam laboratory of Govt. Siddha Medical College, Palayamkottai. 
 
PREPARATION: 
 The purified dried raw drugs are powdered well separately Equal quantity of 
each powdered drugs are then mixed well. Add water Grind it and make it as pills. 
 
Drug storage: 
 The trial drug KALINGA MATHIRAI is stored in clean dry air tight 
container & it is dispensed to the patients in  packets. 
 
 
 
S.NO. DRUG BOTANICAL NAME PART 
USED 
DOSE 
1 AattruThumattiver Citrullus Colocynthis Root 35 gm 
2 Thippili Piper Longum Fruit 35 gm 
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1.Mw;WJkl;b (Aattru thumattiver) 
Botanical Name : Citrullus colocynthis 
Family   :Curcurbitaceae 
English : Colocynth 
Part used : Root 
Rit : ifg;G 
jd;ik : ntg;gk; 
  gphpT: fhh;g;G 
nghJFzk;: 
 fpilnaq;Nf Nrhk;gnyq;Nf NfLwq;nra; thjf; 
 filnaq;Nf ahw;Wf fypq;f - kiljpwf;fpy; 
 mz;il ailr;rnyq;Nf ahapioahh; #jfj;jpd; 
 cz;il Ailr;rnyq;Nf NahJ. 
jPUk; Neha;fs;: 
 fPy;gpbg;ghy; eilapd;wpf; fplj;jy; 
 tspf;Fw;wj;jhy; cz;lhFk; Neha;fs; 
 #yj;jpYz;lhFk; Neha;fs; 
 #jfj; jil 
nra;if: 
Clinical constituents: 
 3-0-Methyl ether, isovitoyin, isoorientin isosaponarin, 2-0-B-D-
glucopyranosylacurbitain hydromethanolic oxtract n-butanol extract. n-B 
Polyphenols, myricetin, gallic acid, polyphends. 
 
2. jpg;gpyp(Thippli) 
NtWngah;  
 Mh;fjp> cz;ruk;> cyitehrp> fhkd;> FNlhhp> NfhioaWf;fp> gpg;gpyp> 
MjpkUe;J 
Botanical name - piper longum 
Family  - Piperaceae 
Part used - fruit  
Rit  : ,dpg;G 
jd;ik : jl;gk; 
gphpT  : ,dpg;G 
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Constituents 
  Piperine, rutin  beto - carpophylleneliperline,  piperamine, lialool 
nra;if 
 ntg;gKz;lhf;fp 
 mfl;Ltha;tfw;wp 
nghJFzk; :  
„fl;bnajph;epd;WfLNehnay;yhk; gzpAk; 
jpl;btpidafYk; Njfnkj;j - Gl;bahk; 
 khkDf;Fkhknkdkw;wth;f;Fkw;wtdhq; 
fhknkDe; jpg;gpypf;Fk; if”          -Njud;ntz;gh 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
EXTERNAL DRUG: KODIVELI THYLAM 
(Ref: GUNAPADAM MOOLIGAI page No 385) 
 
S.NO. DRUG BOTANICAL NAME PART 
USED 
DOSE 
1 Kodiveliver Plumbago zeylanica  Root 35 gm 
2 Thalisa Patheri Taxus buccata Leaf 35 gm 
3 Thantrikai Terminalia bellirica Fruit 35 gm 
4 Karuncheeragam Nigella sativa  Seed 35 gm 
5 Gingely Oil Sesamum indicum Seed 1/2 padi (650ml) 
6 Butter   Punnaikai (6gm) 
7 Cow Milk   Required Amount 
 
PURIFICATION: 
 All above drugs are purified under the formulation of “Anupoga Vaithiya 
Bramma Ragasiyam and Sarakku Suthi Muraigal” 
 
METHOD OF PREPARATION  
 Dried drugs  are Grind with cow milk and mix the powder with oil and heat 
until required consistency formed filter it then kept in a dry air tight container. 
 
INDICATIONS: 
 It is indicated externally for Joint Pain. 
1. nfhbNtyp 
NtWngau;fs;: ntz;rpj;jpu%yk;> ntz;nfhb%yk.; 
Botanical name: Plumbago zeylanica. 
Family name: plumbaginaceae. 
English name: Ceylon lead- wort 
Part used: Root ;> Root bark. 
Rit: fhh;g;G> tpWtpWg;G 
jd;ik: ntg;gk; 
gpupT: fhh;g;G 
 
 
118 
 
nghJf;Fzk;:  
   fl;btpu zq;fpue;jp fhy;fs; miuahg;Gf; 
     fl;br;# iytPf;fq; fho;%yk; -Kl;buj;jf; 
     fl;LeP Nuw;wq; fdj;j ngUtapWk; 
     ml;Lq; nfhbNtyp ahk;. 
jPUk;Neha;fs;:fl;b> Gz;> foiy> tspNeha;> miuag;Gf;fl;b> Fj;jy;> Nrhig> 
%yNuhfk;> cjpufl;L> ePNuw;wk;> ngUtapW Nghk;.  
 
nra;if: Kiwntg;gfw;wp> tpah;itAz;lhf;fp. 
 
Chemical Constituents: plumbagin, isoshinanolone , plumbagic acid, beta-sitosterol, 
4-hydroxybenzaldehyde, trans-cinnamic acid, vanillic acid, 2, 5-dimethyl-7-
hydroxychromone, indole-3-carboxaldehyde . 
 
2. fUQ;rPufk; 
NtWngau;fs;: muzk; , cgFQ;rpif. 
Botanical name:Nigella sativa. 
Family name: Ranunculaceae 
English name: Black cumin 
Part used: Seed  
Rit: ifg;G 
jd;ik: ntg;gk; 
gpupT: fhu;g;G 
nghJf;Fzk;: 
fUQ;rP ufe;jhd; fug;gndhL Gz;Zk; 
tUQ;rpuha;g; gPerK khw;Wk;-mUe;jpdhy; 
fha;r;ry; jiytypAq; fz;typAk; NghKyfpy; 
tha;r;r kUe;njdNt it. 
jPUk; Neha;fs;: kz;il fug;ghd; , Gz; ,cl;#L, jiy Neha; ,fz;Nzha,; 
rpuq;F, tapw;Wg; nghUky; , Fd;kk; , khu;Gtyp, ,Uky; , the;jp, Xf;fhsk; , 
fhkhiy Mfpait jPUk;. 
nra;if: rpWePu;ngUf;fp, UJTz;lhf;fp, ghw;ngUf;fp, grpj;jPj;J}z;b, 
J}f;FzpGOf;nfhy;yp, twl;rpafw;wp. 
Chemical Constituents: Cuminaldehyde, cymene, terpenoids, essential oil. 
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3. jhsprgj;jpup 
Botanical name:Abies spectabilis 
Family name:Pinaceae 
English name: Flaurtia calapharacta 
Part used: Leaf 
Rit: fhu;g;G 
jd;ik: ntg;gk 
gpupT: fhu;g;G 
nghJf;Fzk;:  
ehrp fsg;gpzpfs; ehl;gl;l -fhrQ;R 
  thrk; mUrp tdkq;fhy; -tPrptU 
  Nkfke;jk; mj;jpRuk; tpl;NlFe; jhspr;rj;jhy; 
  MFQ; Rfg;gpur tk;. 
jPUk; Neha;fs;: fopr;ry; , Ruk; , ehl;gl;l ,Uky; , ,iug;G, the;jp, tha;T, 
mrPhzk; , mj;jpRuk; jPUk;. ,jdhy; Rfg;gpurtk; cz;lhFk;. 
nra;if: grpj;jPj;J}z;b, mfl;Ltha;tfw;wp, Nfhioafw;wp, cukhf;fp. 
 
4. jhd;wpf;fha; 
NtWngau;fs;: mf\k;, mKjk,; vupfl;gyk;;, fe;Jfd;;, rfjk;, tpgPjfk; . 
Botanical name: Terminalia bellirica 
Family name: Combretaceae 
English name: Beleric myrobalans 
Part used: Seed 
Rit: Jtu;g;G  
jd;ik: ntg;gk; 
gpupT: ,dpg;G 
nghJf;Fzk;: 
rpye;jptplk; fhkpag;Gz; rPohd Nkfq; 
fye;JtUk; thjgj;jq; fhNyh-lyu;e;Jlypy; 
Cd;wpf;fha; ntg;g Kjpugpj; Jq;fuf;Fe; 
jhd;wpf;fha; ifapnyLj; jhy; 
Mzpg;nghd; Nkdpf; foFk; xspAkpFk; 
Nfhzpf;nfhs; thjgpj;jf; nfhs;ifNghk;-jhdpf;fha; 
nfhz;ltu;f;F NkfkWk; $wh mdw;wpzAk; 
     fz;ltu;f;F thjk;Nghk; fhz; 
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jPUk; Neha;fs;: rpye;jpeQ;R, Mz;Fwpg;Gz; , nts;is, FUjpaoy;Neha; , tsp jP 
Fw;wq;fshy; tUk; Neha;fs; Nghk;.clw;F moifAk; xspiaAk; nfhLj;J 
Kf;Fw;wq;fisAk; jd;dpiyg;gLj;Jk;. 
nra;if: Jtu;g;gp, Nfhioafw;wp, kykpsf;fp, cukhf;fp  
Chemical Constituents: Beta-sitosterol, gallic acid, ellagic acid, ethyl gallate, galloyl 
glucose, chebulagic acid,Tanin. 
 
5. gRk;ghy; 
NtWngaH :  gaR> Rij> Jj;jk;> fPuk;> gak;> mKJ 
nghJFzk;:  
ghyH fpotH goQ;Ruj;NjhH Gz;zhsp 
R+iyaH JHg;gyj;NjhH NkfNehahsp VYkptH 
vy;yhHf;F khFk; ,isj;jtHf;FQ; rhjfkha; 
ey;yha; gRtpd;ghy; ehl;L 
nghUs; : ghyH Kjy; fpotH tiu MFk; R+iy> Nkf Neha; ePq;Fk;. 
 
6. ey;nyz;nza; (vs;) 
  (vs;spy; ,Ue;J ey;nyz;nza; jahhpf;fg;gLfpwJ) 
Botanical Name : Sesamum Indicum 
Family : Pedaliaceae 
Part Used : Seed 
Rit : ,dpg;G 
jd;ik : ntg;gk; 
gphpT : ,dpg;G 
Therapeutic Actions : Emmlnagogie, Stimulant, Tonic, Diuretic,  
       Galactogogce. 
Chemical Constituents  :   Vitamin E, Sesamin, Segamolin, Phytosterol. 
nghJFzk;: 
fz;Zf;F xspiaAk; clYf;F td;ikAk; jUk; 
FUjp ngUf;if cz;lhFk; 
   - mfj;jpaH Fzthflk; 
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EXTERNAL THERAPY(PATTRU) 
Ref:GUNAPADAM  MOOLIGAI Page No:61  
External therapy : PATTRU 
Gunapadam  : Mooligai  
 
S.No. Drug Botanical Name Drug Used Dose 
1 Aakasa garden Corallocarpus epigaeus Root 10g 
2 Vengayam Allium cepa Bulb 10g 
3 Chirakam Cuminum cyminum seed 10g 
4 Amanarkku 
ennai 
Ricinus communi seed 10ml 
 
Purification: 
 All aove drugs are purified under the formulation of „Anupoga Vaithiya 
Bramma Ragasiyam and Sarakesan Suthi Muraigal” 
 Method of preparation: 
             All above drugs are powdered and mix the powder with oil heat the mixure 
and applied in knee joint as pattru. 
Indication: 
 It is indicated externally for Joint pain. 
Drug Storage: 
 The trial drug Pattra is stored in clean dry air tight container it is depensed to 
the patients in pack 
 
1.Mfhrf; fUld; 
Botanical Name: Corallocampus Epigueus  
  
English Name : Bryoms 
Part used : Root 
Rit   : ifg;G 
jd;ik  : ntg;gk; 
gphpT  : fhh;g;G 
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nghJ Fzk;: 
 Jg;ltplk; ghz;L ntg;G #iyth jq;fpue;jp 
 Fl;lk; mhpg;gf;fp Nfhz;Fly;Neha; - nfl;lfz;l  
 khiyNgha; nfhy;yd;Nfh itf;fpoq;fhy; Kj;Njhl 
 NtiyNghk; ghhpy; tpsk;G 
jPUk; Neha;fs;: 
 ghz;L> ntg;G> #iy> fpue;jp> Fl;lk;> fPy;gpbg;G> fPy;thjq;fs; NghFk;. 
nra;if: clw;Nws;sp> cukhf;fp 
Chemical constituents: 
 Ap - hydrocybenzoyl aster, a sestortepene lactone, corallocarpscalarolide, a 
pyridine caryoxylic ester, 2-Mehylheryl p-hydroxybenzoate, Dyridine 3‟ - caryoxylic 
acid ester. 
 
2.rpd;dntq;fhak;   (Vengayam) 
Botanical Name: Allium coper 
English : Onion 
part used : bulb 
Rit  : ifg;G 
jd;ik : ntg;gk; 
gphpT  : fhh;g;G 
nghJFzk;: 
 ntg;gK yq;fpue;jp tPWuj;j gpj;jKld; 
 nrg;Geu mffue;jP uhj;jhfk; - ntg;Gf; 
 fLg;gJke; jQ;re;jp fhrk;tapW Wg;gy; 
 jbg;NgWk; ntq;fha;jhy; 
jPUk; Neha;fs;: 
 fpue;jp> gpj;jk;> ntg;G> fhrk;> tapw;Wg;gy; 
nra;if: 
 ntg;gKz;lhf;fp> rpWePh;ngUf;fp> Nfhioafw;wp> #jfKz;lhf;fp> 
cs;soyhw;wp. 
Chemical Constituents: 
 quercetin, fructose, querctin-3-glucoside, isorhamnetin-4-glucoside, xylose, 
gallactose, glucose, Mannoke, organo solfur compounds, a llyl sulfides, flownoids, 
cycloilline, sulfur 
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3.rPufk;(Seeragam) 
NtW ngau;fs;;: mir, rPup, cgFk;gPrk;, ew;rPup, Jj;jrhk;gyk,; gpj;j ehrpdp, 
Nghrd FNlhup, Nkj;jpak;. 
Botanical Name: Cuminum cyminum 
Family Name: Apiaceae 
Part Used: Seeds 
Rit: fhu;g;G 
jd;ik: jl;gk; 
gpupT: ,dpg;G 
nra;if: mfl;Ltha;tfw;wp,ntg;gKz;lhf;fp,grpj;jPj;J}z;b. 
Chemical Constituents: Essential oil-thymene, cuminol, cumic aldehyde. 
nghJf;Fzk; : 
           thAnthL ehrpNeha; td;gpj;jQ; NruhJ 
           fhak; nefpohJ fz;FspUe; - J}akyu;f; 
           fhusfg; ngz;kapNy! iffz;l jpj;jidAQ; 
           rPufj;ij ePjpdKe; jpd; 
                                      -mfj;jpau; Fzthflk; 
4.Mkzf;F vz;nza; (tpsf;nfz;nza;) 
Botanical Name  : Ricinus Communis 
Family  : Euphorbiaceae. 
NtW ngaH  : Vuz;lk;> rpj;jpuk;> jy&gk; 
Part Used  : Seed 
Rit  : frg;G 
tPhpak;  : ntg;gk; 
gphpT  : fhHg;G 
Therapeutic Actions  :  Laxative, Emollient 
Chemical Constituents :  Ricinine, Ricin, Resin 
nghJFzk;:  
Mkzf; nfz;nza; jd;id azpepy kwpa Nfz;kpd; 
G+kzr; re;JNjhWk; nghUe;jpa thjk; Nghf;Fk; 
jPke;jj; jhDk; Nghf;Fe; jpfo;Tld; tpiuT Kz;lhk; 
jPkdf; Flypy; thjQ; NrHFl Nyw;wk; NghNk 
- vL 
nghUs; : Mkzf;nfz;nzapdhy; thjk; ePq;Fk;. 
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ANNEXURE-11 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
 
BIOCHEMICAL ANALYSIS OF SIDDHA POLYHERBAL DRUG 
KALINGA  MATHIRAI 
Prepaeation of the extract: 
 5 grams of the drug was weighed accurately and placed in a 250ml clean 
beaker. Then 50ml of distilled water added to it and dissolved well. Then it was 
boiled well for about 10 minutes. It was cooled and filtered in a 100ml volumetric 
flask and then it is made upto 100ml with distilled water. This fluid was taken for 
analysis. 
QUALITATIVE ANALYSIS 
S. 
No. 
EXPERIMENT OBSERVATION INFERENCE 
1 
TEST FOR CALCIUM 
2ml of the above prepared extract is 
taken in a clean test tube. To this add 
2ml of 4% Ammonium oxalate 
solution. 
A white precipitate 
is formed 
Indicates the 
presence of 
calcium. 
2 
TEST FOR SULPHATE 
2ml of the extract is added to 5% 
Barium Chloride solution 
A white precipitate 
is formed 
Indicates the 
presence of 
sulphate 
3 
TEST FOR CHLORIDE 
The extract is treated with silver 
nitrate solution. 
A white precipitate 
is formed 
Indicates the 
presence of 
chloride. 
4 
TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No brisk effect 
vessence is formed 
Absence of 
Carbonate 
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5 
TEST FOR STARCH 
The extract is added with weak 
iodine solution 
Blue Colour is 
formed. 
Indicates the 
present of Starch 
6 
TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro 
cyanide. 
No blue color is 
formed. 
Absence of ferric 
iron 
7 
TEST FOR FERROUS IRON 
The extract is treated with 
concentrated Nitric acid and 
Ammonium thiocyanate solution. 
Blood red colour is 
formed. 
Indicates the 
presence of 
ferrous Iron. 
8 
TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid 
No yellow 
precipitate is 
formed 
Absence of 
Phosphate 
9 
TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent 
No yellow 
precipitate is 
formed. 
Absence of 
Albumin. 
10 
TEST FOR TANNIC ACID 
This extract is treated with ferric 
chloride. 
No blue back 
precipitate is 
formed 
Absence of 
galvanic acid. 
11 
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract. 
It gets decolorized 
Indicates the 
presence of 
unsaturated 
compound 
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12 
TEST FOR THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and add 
8-10 drops of the extract and again 
boil it for 2 minutes 
Colour change 
occurs 
Indicates the 
presence of 
reducing sugar 
13 
TEST FOR AMINO ACID 
One or two drops of the extract is 
placed on a filter paper and dried 
well. After drying 1% Ninydrin is 
sprayed over the same and dried it 
well. 
violet colour is 
formed. 
Indicates the 
presence of 
Amino Acid. 
14 
TEST FOR ZINC 
The extract is treated with Potassium 
Ferro cyanide. 
No white 
precipitate is 
formed. 
Absence of Zinc. 
 
INFERENCE: 
 The Bio chemical analysis of the trial drug kalinga Mathirai was tabulated 
above in table  
 The trial drug Kalinga Mathirai contains. 
1. Calcium 
2. Sulphate 
3. Chloride 
4. Starch 
5. Ferrous Iron 
6. Unsaturated compound 
7. Reducing sugar 
8. Amino Acid. 
 The mode of action of the trial drug Kalinga Mathirai which brings about the 
Bone Mineralisation osteoblastic and osteoclastic activity in body. May be due to the 
presence of calcium Sulphate, Chloride, Amino acid, Starch, Ferrous Iron in it. 
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ANNEXURES-111 
PHARMACOLOGICAL ANALYSIS 
EFFECT OF KALINGA MATHERAI ON CARRAGEEN-
INDUCED  
LOCALISED INFLAMMATORY PAIN IN ALBINO RATS 
 
The anti-inflammatory activities of KALINGA MATHERAI  at 100 and 200 
mg/kg doses were evaluated using carrageenan-induced paw edema method. The 
inflammation was readily produced in the form of edema with the help of irritant such 
as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea weed 
(Rhodophyceae) and when injected cause the release of prostaglandins by the way it 
produces inflammation and edema. 
 
REQUIREMENTS: 
Animal                                : Albino rat (180-200 g) 
Drugs and chemicals          : Carrageenan (1%w/v), Diclofenac sodium (standard), 
                                              Carboxy methyl cellulose (1%w/v), 
                                              Plethysmo meter. 
Test compounds                :   KALINGA MATHIRAI. 
METHOD: 
Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1)
 
The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the KALINGA MATHIRAI test 
Compounds dissolved with 2 ml sterile water given through orally 30 min before the 
carrageenan treatment. The paw volumes of the test compounds, standard and control 
groups were measured at 60,240,360 minutes of carrageenan treatment with the help 
of  plethysmometer . Mean increase in paw volume was measured and the percentage 
of inhibition was calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
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TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF KALINGA MATHIRAI  
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.50±0.96 - 
Group II 
   Std 
10mg/kg 
I.P.Diclofenac 
sodium 
2.40±0.40 56.36% 
Group III 
KALINGA 
MATHIRAI 
100mg/kg.Orally. 3.16±0.48 42.54% 
Group IV 
KALINGA 
MATHIRAI 
200mg/kg.Orally.  2.90±0.52 47.27% 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
Dose (mg/kg) 10ml/kg 
orally
Paw volume(ml) as 
measured by mercury 
displacement at 6 hour 
5.50±0.96
Percentage inhibition of 
paw edema -
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Results 
Anti- inflammatory activity 
KALINGA MATHIRAI at 100 and 200 mg/kg doeses were tested for their 
Anti- inflammatory activity by using carrageenan Induced rat paw edema 
method and the results are tabulated in table no 1.  The results reveals that   
both extracts of KALINGA MATHIRAI at 100 and 200 mg/kg doses 
possesses significant Anti- inflammatory activity when compared to control 
group at p<0.01. 
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ANALGESIC ACTIVITY OF KALINGA MATHIRAI 
Hot plate method 
Animals  
Young wister albino rats of either sex aged 4-5 weeks, average weight 100-
150 gm were used for the experiment. The ratwere purchased from the animal  jipmer 
. They were kept in standard environmental condition (at 24.0±0°C temperature & 55-
65% relative humidity and 12 hour light/12 hour dark cycle) for one week for 
acclimation after their purchase and fed ICDDRB formulated rodent food and water 
ad libitum. The set of rules followed for animal experiment were approved by the 
institutional animal ethical committee (Zimmermann, 1983). 
Experimental animals of either sex were randomly selected and divided into 
four groups designated as group-I, group-II, group-III and group-IV consisting of five 
Rats in each group for control, positive control and test sample group respectively. 
Each group received a particular treatment i.e. control (1% Tween-80 solution in 
water, 10ml/kg, p.o.), positive control (Diclofenac sodium 10 mg/kg, p.o.) and the test 
sample (drug of 100 mg/kg, p.o. & 200 mg/kg, p.o. respectively). The animals were 
positioned on Eddy’s hot plate kept at a temperature of 55±0.5 0C. A cut off period of 
15 s (Franzotti et al., 2000) was observed to avoid damage to the paw. Reaction time 
was recorded when animals licked their fore or hind paws, or jumped prior to and 0, 
30, 60 and 90 min after oral administration of the samples (Eddy et al., 1953; 
Kulkarni, 1999; Toma et al., 2003). 
Statistical analysis  
GROUP DOSE 
Mean latency before and after drug administration % inhibition 
0 min 30 min 60  min 90 min 30min 60min 90min 
Group I Vehicle 1.26±0.20 1.45±0.26 1.16±0.19 1.58±0.27 - - - 
Group II 10 1.34±0.08 4..2±0.65 6.97±0.645 10.67±1.08 65.47 83.35 85.19 
Group 
III 
100 1.1±0.074 2.27±0.25 4.19±0.76 4.10±0.17 36.12 72.31 61.46 
Group 
IV 
200 1.07±0.08 2.57±0.52 5.34±0.14 4.93±0.5 43.57 78.27 67.95 
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The results of statistical analysis for animal experiment were expressed as mean ± 
SEM and were evaluated by ANOVA followed by Dunnet’s multiple comparisons. 
The results obtained were compared with the vehicle control group. The p<0.05, 
0.001 were considered to be statistically significant 
 
 
 
Result  
Results of hotplate test are presented in Table   for drugs respectively. The 
drug  were found to exhibit a dose dependent increase in latency time when compared 
with control. At 90 minutes, the percent inhibition of two different doses (100 and 200 
mg/kg body weight) was 61.46% & 67.95% respectively. The results were found to be 
statistically significant (p<0.001)  
 
Discussion 
Sidhha is the first system of medicine to emphasize health as the perfect state 
of physical, psychological, social and spiritual components of a human being. The 
fundamental principle of this medicine successfully eliminates the evil side effects 
without losing the beneficial medicinal properties. Diclofenac was used as a reference 
drug in the current study as it has both central, peripheral actions and can significantly 
treat nociceptive pain as in this model.  In the current study, pain threshold increased 
significantly during the period of observation in all the drug treated groups, with 
maximum effect observed in the  drug Kalinga Mathirai at a dose of 200mg/kg as 
0
10
20
30
40
50
60
70
80
90
- - -
30min 60min 90min
% inhibition
Group II 10 1.34±0.08 
4..2±0.65 6.97±0.645 
10.67±1.08
GROUP III 100 1.1±0.074 
2.27±0.25 4.19±0.76 
4.10±0.17
Group IV 200 1.07±0.08 
2.57±0.52 5.34±0.14 
4.93±0.5
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shown in table 1. The analgesic activity of drug was comparable to diclofenac at 30, 
60, 120 minutes appears to be a significant finding and suggests that this drug has a 
slow onset of analgesic action 
 
CONCLUSION: 
Drug possess significant analgesic and anti-inflammatory potential as 
evidenced from the present preclinical study. These findings support the use of drug 
Kalinga Mathirai in traditional system of medicine for the management of pain and 
inflammatory conditions. Further studies are needed to be carried out in other animal 
models of pain and inflammatory to validate its efficacy and to identify the active 
phytoconstituents in the formulation and their targets in pain and inflammatory 
pathways 
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TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY STUDY OF KALINGA 
MATHIRAI 
Effect of Acute Toxicity Study (14 Days) of KALINGA MATHIRAI 
Table no –1   Physical and behavioral examinations. 
Group 
no. 
Dose(mg/kg) 
Observation 
sign 
No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
 
Table no-2    Home cage activity 
Functional  
and 
Behavioural 
observation 
Observation 
5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Body position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 
Approach 
response 
Normal 3 3 3 3 3 
Touch 
response 
Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response 
Normal 3 3 3 3 3 
134 
 
Table no-3  Hand  held  observation 
Functional 
and 
Behavioral 
observation 
Observation Control 5 mg/ 
kg 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex 
Normal 3 3 3 3 3 3 
Abdominal 
tone 
Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Table no-4  Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
KALINGA MATHIRAI at a dose of 2000 mg/kg to the rats do not produce drug-
related toxicity and mortality. So No-Observed-Adverse-Effect- Level (NOAEL) of 
KALINGA MATHIRAI is 2000 mg/kg. 
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DISCUSSION 
  KALINGA MATHIRAI was administered single time at the dose of 
5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behavioural signs of any toxicity due 
to administration of KALINGA MATHIRAI at the doses of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
KALINGA MATHIRAI on the growth rate. Body weight change in drug treated 
animals was found normal. 
 
INTERPRETATION: 
 KALINGA MATHIRAI was administered single time at the dose of 
5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behaviou ral signs of any toxicity due 
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to administration of KALINGA MATHIRAI at the doses of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
Body weight at weekly interval was measured to find out the effect of 
KALINGA MATHIRAI on the growth rate. Body weight change in drug treated 
animals was found normal. 
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SUB-ACUTE TOXICITY STUDY IN WISTAR RATS TO EVALUATE 
TOXICITY PROFILE OF KALINGA MATHIRAI 
Table :5 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF KALINGA 
MATHIRAI ON BODY WEIGHT IN GRAM 
 
GROUP CONTROL LOW MID HIGH 
1
st
 day 142.3±0.03 125±1.343 124.3±2.131 126.3±2.13 
7
th
 day 132.3±0.03 131.3±1.243 131±2.013 137±2.01 
14
th
 day 134.1±0.004 102.3±1.02 102.4±2.002 103.4±2.002 
21
st
 day 103.3±1.120 110.2±1.401 104±1.031 105±1.03 
28
th
 day 113.3±0.041 112.3±1.102 143±2.0005 146±2.010 
 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group. 
 
EFFECT OF SUBACUTE DOSE (28 DAYS)OF KALINGA MATHIRAI 
Table : 6 KALINGA MATHIRAI ON ORGAN WEIGHT (PHYSICAL 
PARAMETER) IN GRAM 
GROUP CONTROL LOW MID HIGH 
HEART 0.43±0.01 0.34±0.01 0.41±0.01 0.41±0.01 
LIVER 2.31± 0.20 2.33±0.12 2.20±0.01 2.23± 0.13 
LUNGS 0.81±0.05 0.81±0.04 0.50±0.14 0.43±0.05 
KIDNEY L 0.43±0.01 0.52±0.02 0.43±0.01 0.41±0.01 
 R 0.41±0.015 0.48±0.01 0.41±0.014 0.42±0.014 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KALINGA MATHIRAI 
ON HAEMATOLOGICAL PARAMETERS 
Table no 7 
 
Drug 
treatment 
RBC 
million 
cells/cmm 
WBC  
cells/cmm 
Haemoglo
bin gm % 
Differential count % 
Neutop
hils 
Eosinop
hils 
Monoc
yte 
Limpho
cyte 
Control 6.81±0.30 5252.41±2
2.32 
15.40±0.3
5 
41.27±1
.10 
3.53±0.
01 
3.45±0.
05 
23.13±3
.22 
LOW  6.47±0.10 4334.04±2
2.22 
14.20±0.3
3 
35.54±1
.31 
2.10±0.
04 
4.12±0.
20 
23.22±3
.41 
MID 6.03±0.11 5304.25±3
1.35 
13.11±1.0
1 
30.32±2
.12 
1.44±0.
02 
3.32±0.
30 
23.13±3
.21 
HIGH 6.26±0.11 4808.25±3
1.35 
16.11±1.0
1 
28.32±2
.12 
1.50±0.
02 
3.34±0.
30 
24.13±3
.23 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
 
 
Table :8  EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF KALINGA 
MATHIRAI ON BIOCHEMICAL PARAMETERS 
 
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT(IU/L) ALT(IU/L) 
Urea 
(mg/dl) 
Creatinine(mg/dl) 
Control 32.14±3.01 42.24±4.21 243.12±10.32 25.35±3.00 0.94±0.02 
LOW 32.13±3.11 41.23±4.01 251.11±11.42 20.53±2.32 0.60±0.03 
MID 30.21±4.34 44.31±2.11 245.45±4.04 29.12±2.12 0.45±0.03 
HIGH 32.21±4.34 40.31±2.11 234.45±4.04 20.12±2.12 0.46±0.03 
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Table No. : 9 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KALINGA 
MATHIRAI BIOCHEMICAL PARAMETERS 
 
GROUP CONTROL 
KALINGA 
MATHIRAI 
(200mg/kg) 
KALINGA 
MATHIRAI 
(400mg/kg) 
KALINGA 
MATHIRAI 
(600mg/kg) 
TOTAL 
BILIRUBIN 
(mg/dl) 
0.63±0.27 0.8±0.27 0.78±0.76 0.60±0.9 
  
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
 
Table:10 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KALINGA 
MATHIRAI ON FOOD INTAKE IN GRAM 
 
GROUP CONTROL Low mid High 
1
st 
DAY 18.33±12.5110 19.1672±13.3 12.10±20.71 17.5±7.32 
7
th 
DAY 15.5±10.10 10.863±11.67 16.73±9.553 11.17±14.21 
14
th 
DAY 18.83±8.52 10.83±13.28 10±13.86 19.72±8.381 
21
st 
DAY 11.87±12.2 15±7.466 15.88±9.23 19.17±8.01 
28
th
 DAY 12.10±11.18 18.38±10.50 10±8.20 10±7.27 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
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Table:11. Effect of Sub- Acute Dose (28 Days) Of  KALINGA MATHIRAI On 
Water Intake in ml 
GROUP CONTROL 
KALINGA 
MATHIRAI 
(200mg/kg) 
KALINGA 
MATHIRAI 
(400mg/kg) 
KALINGA 
MATHIRAI 
(600mg/kg) 
1
st 
DAY 98.38±13.5110 89.72±14.3426 102.10±21.79 67.5±7.603 
7
th 
DAY 85.5±11.7938 100.863±12.70 76.6673±9.863 81.6717±14.4150 
14
th 
DAY 58.3383±8 90.63±14.2812 80±13.92 89.12±8.81 
21
st DAY
 91.6687±12.9 85±8.462 65.38±9.550 89.1717±8.72 
28
th
 DAY 82.10±11.40 88.38±11.04 80±8.961 70±7.73 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
 
Table: 12  EFFECT OF SUB ACUTE DOSES (28 DAY) OF KALINGA 
MATHIRAI ON ELECTROLYTES: - 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); NS- non-significant, *p<0.05, 
**p<0.01, ***p<0.001,  
 
GROUP CONTROL 
KALINGA 
MATHIRAI 
(200mg/kg) 
KALINGA 
MATHIRAI 
(400mg/kg) 
KALINGA 
MATHIRAI 
(600mg/kg) 
Sodium (mg/dl) 154.90±0.85 154.40±0.92 151.99±0.71 154.70±0.60 
Calcium(mg/dl) 10.5.80±0.89 13.90±0.783*** 14.6±0.99*** 16.10±0.11*** 
Phosphorus 
(U/L) 
10.28±0.07 10.30±0.01
ns 
11.30±0.91
ns 
11.7±0.502* 
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RESULTS: 
CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period 
of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.22 Comparison of organ weights of treated animals with respective 
control animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated 
when compared with those of respective controls; however, the increase or 
decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on the day 29th and 
recorded in Table no 24, 25 revealed the following significant changes in the values 
of hepatic serum enzymes studied. When compared with those of respective 
control. However, the increase or decrease in the values obtained was within 
normal biological and laboratory limits. 
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INTERPRETATION: 
1)  All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29th, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29
th
, no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
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             GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA POLYHERBAL MEDICINE  KALINGA MATHIRAI [INTERNAL], KODIVELI 
THYLUM [EXTERNAL] AND  PATTRU AS EXTERNAL THERAPY FOR THE 
TREATMENT OF AZHEL KEEL VAYU [OSTEOARTHRITIS] 
 
   
FORM-I 
 
 
(SCREENING AND SELECTION PROFORMA) 
 
 
1.OPD/IPD No: ___________   2.Date: _____ 3.SI.No: ________ 4.Name: _________ 
5. Age:  6. Gender:   7. Phone No: . 
    
 
 
INCLUSION CRITERIA 
 AGE: 30-60 Yrs 
 Sex : Both male and female 
 Patients having symptoms of joint pain of  both knee joints, swelling, tenderness,   
  stiffness, criptations, restricted movements of both knee joints. 
 Patients who are willing to give blood samples for laboratory investigation . 
 Patients who are willing to take X-ray before and after treatment.  
 Patients who are willing to participate in this study with the knowledge of 
potential risks. 
EXCLUSION CRITERIA 
 Cardiac disease 
Rheumatoid arthritis 
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 Use of narcotic drugs 
 Pregnant women  and lactating mother 
 History of trauma 
 Patient with any other serious illness. 
 Benign and malignant neoplasm 
 Immuno compromised Patients 
 Children, elderly  
  
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of adverse reactions during drug trial. 
 Poor patient compliance & defaulters. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness. 
 
DATE : 
 
STATION : Signature of the Investigator 
 
 
 
Signature of the Guide/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
POLYHERBAL MEDICINE KALINGA MATHIRAI [INTERNAL], KODIVELI THYLUM 
[EXTERNAL] AND  PATTRU AS EXTERNAL THERAPY FOR THE TREATMENT OF AZHEL KEEL 
VAYU[OSTEOARTHRITIS] 
 
FORM-II 
 
CONSENT FORM 
 
Certificate by Investigator 
 
I certify that I have disclosed all details about the study in the terms readily understood by the 
 
Patient. 
 
Date: …………….. 
 
Signature of the 
 
Signature of the Investigator: …………….. 
 
Guide/HOD: ……………………. 
 
Name: …………………………….. 
 
Name: …………………………… 
 
Consent by Patient 
 
I have been informed to my satisfaction, by the attending physician, the purpose of the clinical 
trial, and the nature of drug treatment and follow-up including the laboratory investigations to be 
performed to monitor and safeguard my body functions. 
 
I am aware of my right to withdraw from the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 
I, exercising my free power of choice, hereby give my consent to be included as a clinical trial of 
KALINGA MATHIRAI[INTERNAL] KODIVELI THYLAM [EXTERNAL] AND  PATTRU as EXTERNAL THERAPY FOR THE 
TREATMENT OF AZHEL KEEL VAAYU[OSTEOARTHRITIS] 
 
Date: ……………….. Name: …………… 
 
Signature: ………………………………… 
 
 
Date: ……………….. Name: ……………… 
 
Signature of Witness: ……………………. 
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murpdH rpj;j kUj;Jtf; fy;Yhhp kw;Wk; kUj;Jtkid 
 
ghisaq;Nfhl;il 
 
gl;lNkw;gbg;G rpwg;G kUj;Jtj;Jiw 
 
 
 
‘fypq;f khj;jpiu” kw;Wk; ‘nfhbNtyp ijyk;; - xw;wlk;” ,tw;wpd; ghpfhpg;Gj; jpwidf; 
fz;lwpAk; kUj;Jt Ma;T xg;Gjy; gbtk; Ma;thsuhy; rhd;wspf;fg;gl;lJ. 
 
 
 
ehd; ,e;j Ma;itf; Fwpj;j midj;J tpguq;fisAk; Nehahspf;F GhpAk; 
tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
 
 
Njjp : 
 
,lk; : 
 
Ma;thsh; ifnahg;gk;: 
 
ngau;: 
 
 
Jiwj;jiytu; 
 
ifnahg;gk;: 
 
ngaH: 
 
 
Nehahspapd; xg;Gjy; 
 
vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk; kUe;jpd; jd;ik kw;Wk; kUj;Jt 
topKiwiag; gw;wpAk; njhlHe;J vdJ cly; ,af;fj;ij fz;fhzpf;fTk;> mjidg; 
ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l ghpNrhjidfs; gw;wpAk; jpUg;jp mspf;Fk; 
tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
 
ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;nghOJ 
Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;Jf; nfhs;Sk; chpikia 
njhpe;jpUf;fpd;Nwd;. 
 
 
ehd; vd;Dila Rje;jpukhfj; NjHT nra;Ak; chpikiaf; nfhz;L gf;fthA 
vd;Dk; Neha;f;fhd ty;yhjp ,urhazk; kw;Wk; rh;thq;f thj ijyk; - xw;wlk; 
Mfpatw;wpd; ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;F vd;id 
cl;gLj;jpf;nfhs;s xg;Gjy; mspf;fpNwd;. 
 
 
 
Njjp : 
 
,lk; : 
 
 
 
ifnahg;gk;: 
 
ngaH : 
 
rhl;rpf;fhuH ifnahg;gk;: 
 
ngaH: 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA POLYHERBAL MEDICINE KALINGA MATHIRAI[INTERNAL], KODIVELI 
THYLUM[EXTERNAL] AND  PATTRU AS EXTERNAL THERAPY FOR THE 
TREATMENT OF AZEL KEEL  VAYU[OSTEOARTHRITIS] 
 
FORM III 
 
HISTORY PROFORMA ON ENROLLMENT 
 
1. Serial No of the case:  _______________       2. OPD/IPD No:_________ 
              
3.Name: ____________           4. Gender:   
5. Age (years): _________ DOB 
             
             
             
    Date Month Year 
6. Address: --------------------------------------              
  --------------------------------------           
  --------------------------------------           
7. A. Occupation:   -----------------------------        B. Income ----------------- 
         
8. Educational Status:  A) Illiterate   B)Literate       
              
9. Height: ---------- cms 10.Weight:----------  kg       
 
11. Complaints and Duration: 
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12. Past History  
Hypertension ______________ 
Diabetes mellitus ______________ 
Asthma ______________ 
PT ______________ 
Other ______________ 
 
13. HABITS                            
                           
A) Smoking : 1. Yes    duration ________ years;  Number - _____   2. No      
                           
                        
B) Alcoholism:1. Yes    duration ________ years;  Quantity- ____ ml 2. No      
                         
                     
C) Tobacco chewing: 1. Yes    duration ________ years     2.No      
                             
D) Betel chewing : 1. Yes    duration ________ years     2.No      
                        
                    
14. Dietary style: A.Pure vegetarian     B.Non-vegetarian    C. Mixed diet   
                  
15. Drug history: Had the patient been treated before with allopathy drug? 
  
A) Yes 
        
2) No 
               
                         
16 Marital status : 1.Married 
     
2.Unmarried 
             
                  
                  
17. Family history : 
                         
                         
                  
 Whether this problem runs in family?  1. Yes       2.No       
 
(If yes, mention the relationship) 
                     
                      
18. Bowel habits & micturition:Normal 
   
Abnormal 
  
     
 
(Details of an abnormality) 
                     
                      
19. Psychological state: Normal 
     
Anxiety 
   
Depression 
  
          
                
Signature of the Investigator          Signature of the Guide/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA POLYHERBAL MEDICINE KALINGA MATHIRAI [INTERNAL], KODIVELI 
THYLUM [EXTERNAL] AND  PATTRU AS EXTERNAL THERAPY FOR THE 
TREATMENT OF AZHEL KEEL VAYU [OSTEOARTHRITIS] 
 
FORM IV 
 
CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1. S.No:  _______ 2. OPD/IPD No : __________ 
3. Name: _______________________ 4. Gender: __________ 
 
5. Date of assessment: _____________ 
 
SIDDHA SYSTEM OF EXAMINATION 
 
 
 
1.NILAM: [ LAND WHERE PATIENT LIVED MOST]     
           
Kurinji  Mullai  Marutham   Neithal  Palai  
           
(Hilly terrain) (Forest range) (Plains) (Coastal belt) (Arid regions) 
 
 
 
2. KAALAM:     
Kaarkalam - 
 
Pinpanikalam -  
Koothirkalam - 
 
Ilavenil - 
 
 
Munpanikalam - 
 
Muthuvenil - 
 
 
      
 
 
3.THEGI: 
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4. GUNAM:  
 
Sathuvam  -  Rasatham -  Thamasam  - 
     
 
5.IMPORIGAL (SENSORY ORGANS) : 
 
Mei (Skin) : 
 
Vai (Buccal Cavity): 
 
Kan(Eyes) : 
 
Mooku(Nose): 
 
Sevi(Ears) : 
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
 
Kai (Upper limb): 
 
Kaal(Lower limb): 
 
Vai(Buccal Cavity): 
 
Eruvai(Excretory organs): 
 
Karuvai(Reproductive organs): 
 
 
 
7.UYIR THATHUKKAL: 
 
A)VATHAM: 
 
Pranan: 
 
Abanan: 
 
Viyanan: 
 
Udhanan: 
 
Samanan: 
 
Nagan: 
 
Koorman: 
 
Kirukaran: 
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Devathathan: 
 
Dhananjeyan: 
 
B)PITHAM: 
 
Analpitham: 
 
Ranjagam: 
 
Sathagam: 
 
Prasagam: 
 
Aalosagam: 
 
C)KABAM: 
 
Avalambagam: 
 
Kilaethagam: 
 
Pothagam: 
 
Tharpagam: 
 
Santhigam: 
 
8.UDAL THATHUKKAL: 
 
Saaram[Chyme]: 
 
Senneer[Blood]: 
 
Oon[Muscle]: 
 
Kozhuppu[Fat]: 
 
Enbu[Bone]: 
 
Moolai[Bone Marrow]: 
 
Sukkilam/Suronitham 
[Genital Discharges] : 
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9.ENVAGAI THERVUGAL: 
 
Naadi: 
 
Sparisam: 
 
Naa: 
 
Niram: 
 
Mozhi: 
 
Vizhi: 
 
Malam: 
 
Moothiram: 
 
 
10.NEER KURI: 
 
Niram: 
 
Manam: 
 
Nurai: 
 
Edai: 
 
Enjal: 
 
 
 
 
11.NEI KURI: 
 153 
 
GENERAL EXAMINATION: 
 
Conscious level: 
 
Body weight: 
 
Height: 
 
BMI: 
 
Built: 
 
Nourishment: 
 
Temperature: 
 
Blood Pressure: 
 
Pulse rate: 
 
Heart rate: 
 
Respiratory rate: 
 
Anaemia: 
 
Jaundice: 
 
Clubbing: 
 
Cyanosis: 
 
Pedal oedema: 
 
Significant Lymphadenopathy: 
 
 
 
SYSTEMIC EXAMINATIONS: 
 
Central Nervous System: 
 
Cardio Vascular System: 
 
Respiratory System: 
 
Gastro Intestinal System: 
 
Genito Urinary System: 
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 EXAMINATION OF JOINT: 
 
Joint Involvement : Single/Poly 
Morning Stiffness: 
Pain Type;Recurrent attack/Episodic/Flitting or Migratory 
INSPECTION: 
 Spinal deformities:Kyphosis/Scoliosis/Lordosis/None 
Swelling: 
Deformity: 
PALPATION: 
Tenderness: 
Heat: 
Fluid accumulation: 
Crepitus: 
MOVEMENTS: 
 
 
 
 
 
 
SPECIFIC EXAMINATION: 
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CLINICAL ASSESSMENT FORM 
 
PAIN ASSESSMENT 
UNIVERSAL PAIN ASSESSMENT SCALE 
 
 
A -0  - No pain 
B-1-3  - Mild pain 
C-4-6  -           Moderate pain 
D-7-10              - Severe pain 
Reference: Clinical manual for Nursing practice (National Institute of Health warren grant 
mangneson clinical centre) 
GRADATION OF MOVEMENTS: 
 G1 - Fit for all activities, do their work without support. 
 G11 - Mild pain present in knee joint, mild restricted movement 
 G111 - Moderate pain present in knee joint, moderate restricted  
                      movements, need some assistance to perform 
 G1V - Severe pain, bed ridden 
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Signature of the Investigator Signature of the Guide/HOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO SIGN & SYMPTOMS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
1. PAIN   
2. SWELLING   
3. REDNESS   
4. HEAT   
5. RESTRICTED 
MOVEMENTS 
  
6. CRIPITUS   
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA POLYHERBAL MEDICINE KALINGA MATHIRAI [INTERNAL]KODIVELI 
THYLAM [EXTERNAL] AND  PATTRU AS EXTERNAL THERAPY FOR THE 
TREATMENT OF AZHEL KEEL VAAYU[OSTEOARTHRITIS] 
 
FORM V 
LABORATORY INVESTIGATION FORM 
SI.No: 
OPD/IPD No: 
Name: 
Age/Sex: 
 
I.BLOOD 
 
  Before Treatment After Treatment 
1 TC (cells/mm)   
    
2 DC (%)   
    
 a)Neutrophils   
    
 b)Lymphocytes   
    
 c)Monocytes   
    
 d)Eosinophils   
    
3 ESR(mm)   
    
 a)1/2 hour   
    
 b)1 hour   
    
4 Haemoglobin   
    
5 Blood glucose   
    
6 Blood urea/ creatinine   
    
7 Serum cholesterol    
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II. URINE 
 
  Before Treatment After Treatment 
    
1 Albumin   
    
2 Sugar   
    
3 Epithelial cells   
    
4 Pus cells   
    
5 Red blood cells   
    
6 Casts/Crystals   
    
 
 
 
 
 
 
Date 
 
 
 
 
 
: 
 
Station 
 
: 
 
Signature of the Investigator 
 
: 
 
 
 
Signature of the Guide/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA MONOHERBAL MEDICINE KALINGA MATHIRAI [INTERNAL], KODIVELI 
THYLAM[EXTERNAL] AND  PATTRU ase EXTERNAL  THERAPY FOR THE 
TREATMENT OF AZHAL KEEL VAYU [OSTEOARTHRITIS] 
 
FORM VI 
 
(DRUG COMPLIANCE FORM) 
 
OPD/ IPD No: ____________ 
 
DOA : ___________ 
 
Name: _____________________ 
 
 
Age/Sex: ___________ Sl.No: _________ 
 
Name of the Drug : KALINGA MATHIRAI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DATE: 
 
SIGNATURE OF THE INVESTIGATOR SIGNATURE OF THE GUIDE/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA MONOHERBAL MEDICINE KALINGA MATHIRAI [INTERNAL], KODIVELI 
THYLAM  [EXTERNAL] AND  PATTRU as EXTERNAL  THERAPY FOR THE 
TREATMENT OF AZHAL KEEL VAYU [OSTEOARTHRITIS] 
 
FORM VII 
 
ADVERSE DRUG REACTION FORM 
 
 
 
 
Name: ________________________ OPD/ IPD No: __________ 
 
Age: ________ Gender: ________ 
 
Date of trial commencement: ___________ 
 
Date of withdrawal from trial: ___________ 
 
 
Description of adverse reaction: _______________________________________________ 
 
________________________________________________________________________ 
 
 
 
Date: 
 
Station: 
 
 
 
 
SIGNATURE OF THE INVESTIGATOR SIGNATURE OF THE GUIDE/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA POLYHERBAL MEDICINE KALINGA MATHIRAI [INTERNAL], KODIVELI 
THYLAM[EXTERNAL] AND  PATTRU AS EXTERNAL THERAPY FOR THE 
TREATMENT OF AZHEL KEEL VAAYU[OSTEOARTHRITIS] 
 
 
 
   FORM VIII    
  WITHDRAWAL FORM  
Name: ________________________ OPD/ IPD Number: __________  
Age : ________  Gender : ________   
Date of trial commencement: ___________       
Date of withdrawal from trial: ___________       
Reasons for withdrawal:      YES NO 

        
Long absence in without reporting :      
 Irregular treatment 
  
: 
      
        
       
 Shift of locality 
  
: 
      
       
       
  Increase in severity of symptoms : 
      
      
     
      
            
 
 Development of severe adverse drug reactions : 
 
Date : 
 
Station : 
 
SIGNATURE OF THE INVESTIGATOR SIGNATURE OF THE GUIDE/HOD 
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